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Gastric	   cancer	   is	   the	   fifth	   most	   common	   malignancy	   in	   the	   world	   and	   third	   the	  
leading	  cause	  of	  cancer-­‐related	  mortality	  worldwide,	  with	  five-­‐year	  survival	  rate	  of	  only	  20-­‐
29%.	   In	   order	   to	   develop	   better	   drugs,	   diagnostics	   and	   preventive	   measures	   for	   gastric	  
cancer,	   it	   is	   critical	   to	   understand	   the	   underlying	   molecular	   biology	   of	   the	   disease	   and	  
factors	  that	  increase	  the	  risk	  for	  the	  disease.	  Helicobacter	  pylori-­‐induced	  chronic	  gastritis	  is	  
a	  major	  risk	  factor	  associated	  with	  gastric	  cancer	  development.	  	  
We	   analyzed	   publically	   available	   gene	   expression	   data	   from	   patients	   with	   gastric	  
cancer	  and	  patients	  with	  H.	  pylori	  mediated	  gastritis,	   to	   identify	  genes	  and	  pathways	   that	  
play	   an	   important	   role	   in	   the	   two	   diseases.	  We	   further	   integrated	   the	   identified	   disease	  
signature	  with	  Broad	   Institute’s	  Connectivity	  Map	   to	   identify	  and	  prioritize	  drugs	   that	   can	  
potentially	  reverse	  the	  molecular	  signature	  of	  gastric	  cancer	  cells	  and	  that	  of	  gastric	  tumors	  
resistant	   to	   Cisplatin-­‐Flurouracil	   (CF)	   chemotherapy.	   Our	   analysis	   identified	   vorinostat,	  
trichostatin	   A	   and	   thiostrepton	   as	   potential	   therapeutic	   compounds	   for	   gastric	   cancer	  
treatment.	   We	   identified	   genes	   and	   pathways	   that	   are	   differentially	   expressed	   (57	   up-­‐
regulated	   and	   86	   down-­‐regulated)	   in	   both	   gastric	   cancer	   and	  H.	   pylori	  mediated	   atrophic	  
gastritis.	   The	   topmost	   pathways	   enriched	   for	   these	   genes	   include	   -­‐	   cell-­‐cell	  
adhesion/communication,	  tight	  junctions,	  leukocyte	  transendothelial	  migration,	  gastric	  acid	  
secretion,	   potassium	   ion	   transport	   and	   creatine	   pathways.	   Analysis	   of	   CF	   resistant	   and	  
sensitive	  tumors	  suggests	  the	  role	  of	  metabolic	  and	  statin	  pathways	  towards	  resistance	  to	  
the	  chemotherapy.	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We	   also	   developed	   a	   mathematical	   model	   of	   a	   sub-­‐network	   comprising	   of	   sonic	  
hedgehog	  (SHH),	  pro-­‐inflammatory	  cytokines	  and	  anti-­‐inflammatory	  cytokines,	  which	  play	  a	  
critical	   role	   in	   H.	   pylori	   mediated	   gastritis.	   We	   integrated	   qPCR	   results,	   mathematical	  
modeling	   technique	   and	   microarray	   data	   from	   H.	   pylori	   infected	   mice	   to	   explore	   the	  
temporal	  behavior	  of	  the	  cytokine-­‐SHH	  sub-­‐network.	  Our	  mathematical	  model	  suggests	  that	  
NFĸB,	   SHH	   and	   the	   cytokines	   engage	   in	   a	   feedback	   loop	   which	   can	   result	   in	   damped	  
oscillations.	  The	  model	  helps	  to	  bring	  out	  emergent	  properties	  of	  the	  network	  and	  generate	  
testable	  hypotheses.	  Future	  experiments	  capturing	  cytokines	  and	  SHH	  profile	  over	  time	  can	  
reveal	  more	   insights	   about	   the	   relationship	   between	   the	   different	   genes,	   their	   regulation	  
and	  improve	  our	  current	  understanding	  of	  the	  dynamics	  and	  sequence	  of	  the	  events	  in	  the	  
system.	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Chapter 1: Introduction and Motivation 
1.1 Gastric Cancer 
Gastric	  cancer	  is	  the	  fifth	  most	  common	  malignancy	  in	  the	  world	  and	  the	  third	  leading	  
cause	  of	  cancer-­‐related	  mortality	  worldwide	  [1],	  with	  a	  five	  year	  survival	  rate	  of	  only	  20%	  [2]	  
to	   29%	   [3].	   Risk	   factors	   for	   development	   of	   gastric	   cancer	   include	   chronic	   atrophic	  
gastritis,	  Helicobacter	  pylori	  infection,	  smoking,	  heavy	  alcohol	  use,	  and	  high	  salt	   intake	  [4].	  
Helicobacter	  pylori	   is	  one	  of	   the	  most	   significant	   risk	   factor	  associated	  with	  gastric	   cancer	  
[5].	   In	   1994,	  H.	   pylori	  was	   classified	   as	   class	   I	   carcinogen	   by	   the	   International	   Agency	   for	  
Research	  on	  Cancer	  [6].	  H.	  pylori-­‐induced	  chronic	  gastritis	  is	  the	  first	  step	  of	  the	  cascade	  of	  
gastric	  cancer	  development.	  Correa	  proposed	  the	  “human	  model	  of	  gastric	  carcinogenesis”	  
as	   a	   cascade	   that	   includes	   the	   non-­‐atrophic	   chronic	   gastritis,	  multifocal	   atrophic	   gastritis,	  
intestinal	   metaplasia,	   low-­‐grade	   dysplasia	   (low-­‐grade	   non-­‐invasive	   neoplasia),	   high-­‐grade	  
dysplasia	   (high-­‐grade	   non-­‐invasive	   neoplasia),	   and	   invasive	   adenocarcinoma	   [7,8].	   Non-­‐
atrophic	  gastritis	  can	  be	  either	  cured	  by	  clearing	  H.	  pylori	  infection,	  or	  it	  may	  evolve	  in	  of	  the	  
following	  ways:	  a)	  it	  can	  remain	  as	  non-­‐atrophic	  or	  b)	  it	  can	  progress	  in	  severity,	  damaging	  
gastric	  glands.	  The	  progression	  depends	  on	  interplay	  of	  three	  factors:	  virulence	  of	  infectious	  
agent,	  host’s	  genetic	  susceptibility	  and	  external	  environment	  [9].	  	  
H.	  pylori	  infection	  of	  gastric	  epithelium	  leads	  to	  recruitment	  and	  activation	  of	  immune	  
cells.	   Non-­‐specific	   immune	   response	   involves	   the	   release	   of	   chemokines	   such	   as	   IL-­‐8	   and	  
GRO-­‐alpha,	  and	  pro-­‐inflammatory	  cytokines	   liberated	  by	  mononuclear	  phagocytes	   (TNF-­‐α,	  
IL-­‐1	   and	   IL-­‐6)	   [10,11].	   Antigen-­‐specific	   cellular	   immunity	   results	   in	   a	   predominant	   Th1	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lymphocyte	   response	   with	   increase	   in	   IFN-­‐γ	   secreting	   T-­‐helper	   cells,	   while	   humoral	  
responses	   lead	   to	   the	   production	   of	   anti-­‐H.	   pylori	   antibodies	   and	   complement	   activation	  
[12].	  The	  complex	  network	  of	  cytokines	  implicated	  in	  these	  inflammatory	  responses	  include	  
counter-­‐regulatory	   elements	   such	   as	   IL-­‐10	  which	  may	   serve	   to	   damp	   down	   inflammation	  
[11,13].	  The	  balance	  between	  pro-­‐inflammatory	  and	  immunosuppressive	  cytokines	  is	   likely	  
to	  be	  a	  critical	  determinant	  of	  the	  severity	  of	  H.	  pylori-­‐associated	  inflammation	  [12].	  Chronic	  
cellular	  damage	  leads	  to	  increase	  in	  reactive	  oxygen	  and	  nitrogen	  species	  	  [14,15],	  epithelial	  
cyclooxygenase-­‐2	  and	  activation	  of	  the	  pro-­‐inflammatory	  transcription	  factor	  NF-­‐κB,	  which	  
may	   all	   contribute	   to	   gastric	   cancer	   development	   [16].	   Sonic	   Hedgehog	   (SHH)	   is	   another	  
important	  gene	   that	  has	  been	   reported	   to	  play	  a	   role	   in	  pathogenesis	  of	   chronic	  H.	  pylori	  
infection	  [100,101]	  and	  gastric	  cancer	  [102–105].	  	  
In	   spite	   of	   the	   advancement	   in	   identifying	   the	   host	   susceptibility	   genes,	   the	   precise	  
molecular	  and	  cellular	  details	  of	  how	  H.	  pylori	  associated	  inflammatory	  response	  promotes	  
gastric	  cancer	  development,	  are	  not	  well	  understood.	  Identification	  of	  a	  gene	  signature	  that	  
is	   common	   to	   gastric	   cancer	   and	   H.	   pylori	   mediated	   gastritis	   can	   enhance	   our	   current	  
knowledge	  about	   the	  molecular	  details	  which	   link	   the	  two	  diseases.	  Moreover,	  a	  systemic	  
understanding	  of	   the	  gene	  network	   is	  a	  prerequisite	   for	  enabling	   rational	  manipulation	  of	  
specific	  genes	  and	  pathways	  that	  would	  help	  to	  develop	  in-­‐vivo	  and	  in-­‐vitro	  disease	  models.	  
However,	   such	   experiments	   are	   associated	   with	   high	   cost,	   especially	   time-­‐series	  
experiments.	  Mathematical	  models	  have	  been	  useful	  tools	  for	  understanding	  and	  predicting	  
emergent	   properties	   of	   such	   complex	   systems.	   Models	   provide	   useful	   insights	   towards	  
generating	  new	  hypotheses,	  and	  can	  be	  helpful	   in	   the	  design	  of	   subsequent	  experimental	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studies.	   	   In	  the	  context	  of	  studying	  dynamics	   involving	   interactions	  that	  drive	  the	   immune	  
response	  to	  H.	  pylori,	  alternatives	  for	  interactions	  among	  components	  of	  the	  system	  can	  be	  
explored	   computationally	   in	   order	   to	   yield	   insight	   into	   possible	   dynamic	   modes.	   	   By	  
comparing	   experimental	   data	   and	  possible	   dynamical	  modes,	   it	  may	  be	  possible,	   in	   some	  
cases,	   to	   significantly	   optimize	   experimental	  models	   and	   help	   ameliorate	   complexity	   and	  
cost	  of	  bench-­‐top	  experiments.	  	  
Key	  challenges	  in	  clinical	  management	  of	  gastric	  cancer	  are	  late	  diagnosis	  and	  limited	  
success	  rate	  of	  currently	  available	  drugs.	  Early	  diagnosis	  of	  gastric	  cancer	  is	  difficult	  as	  most	  
patients	  are	  asymptomatic	   in	  early	   stages.	  Weight	   loss	  and	  abdominal	  pain	  are	  often	   late	  
signs	   of	   tumor	   progression	   [17].	   Treatment	   options	   include	   surgery,	   chemotherapy	   and	  
radiation	   therapy.	   Unfortunately,	   most	   cases	   are	   diagnosed	   in	   later	   stages	   [17]	   and	  
advanced	   gastric	   cancer	   is	   generally	   refractory	   to	   chemotherapy	   [18];	   with	   the	   five	   year	  
survival	  rate	  of	  less	  than	  40%	  for	  patients	  who	  undergo	  surgery	  [19].	  Target	  based	  therapy,	  
which	  blocks	  the	  growth	  of	  cancer	  cells	  by	  interfering	  with	  specific	  targeted	  molecules	  that	  
are	  required	  for	  carcinogenesis	  and	  tumor	  growth,	  has	  emerged	  as	  a	  new	  tool	  in	  treatment	  
of	   cancer	   [20].	   Combination	   of	   target	   based	   drugs	  with	   standard	   cytotoxic	   chemotherapy	  
has	   shown	   promising	   results	   in	   some	   cancers;	   for	   example,	   breast	   cancer	   (Trastuzumab,	  
Lapatinib),	   non-­‐small	   cell	   lung	   cancer	   (Erlotinib,	   Gefitinib)	   and	   renal	   cell	   carcinoma	  
(Sunitinib)	  [20].	  However	  development	  of	  target	  based	  drugs	  for	  gastric	  cancer	  treatment	  is	  
challenging	  due	  to	  limited	  or	  absence	  of	  biomarker	  knowledge,	  and	  heterogeneous	  nature	  
of	   the	  disease.	  Currently,	   there	  are	  only	   two	  FDA	  approved	   target	  based	  drugs	   for	  gastric	  
cancer	   treatment	   –	   Trastuzumab	   (targeting	   HER2)	   [21]	   and	   Ramucirumab	   (targets	   VEGF)	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[22].	   Clearly,	   there	   is	   an	   urgent	   need	   for	   development	   of	   more	   drugs	   for	   gastric	   cancer.	  
However,	  drug	  development	  is	  a	  long	  and	  expensive	  process.	  The	  average	  cost	  and	  time	  for	  
developing	  a	  new	  drug	   is	  approximately	  1-­‐2	  billion	  dollars	  and	  10	  years,	   respectively	   [23].	  
Moreover,	  the	  rate	  of	  failure	  of	  a	  new	  lead	  compound	  in	  clinical	  phase	  is	  high,	  especially	  for	  
oncology	  drugs	  [24].	  	  
One	  of	  the	  approaches	  that	  may	  help	  reduce	  the	  high	  cost	  and	  time	  associated	  with	  
drug	   discovery	   is	   repurposing	   drugs	   approved	   for	   other	   diseases.	   A	   major	   advantage	   of	  
repositioning	  drugs	  is	  their	  established	  safety	  profile	  (in	  cases	  where	  doses	  regiments	  do	  not	  
change	  significantly).	  Identification	  of	  molecular	  signature	  derived	  from	  disease	  omics	  data,	  
with	  or	  without	  drug	  treatment,	  can	  be	  help	  to	  prioritize	  existing	  drugs	  for	  treatment	  of	  the	  
disease.	   Gene	   expression	   profiling	   can	   help	   identify	   genes	   that	   may	   serve	   as	   candidate	  
biomarkers	   and	   the	   profiles	   be	   can	   used	   for	   other	   applications	   such	   as	   for	   diagnosis,	  
prognosis,	  sub-­‐classification	  of	  the	  disease,	  response	  to	  specific	  drugs	  and	  as	  potential	  drug	  
targets.	   For	   example,	   OncotypeDx,	   MammaPrint	   and	   Mammostrat	   are	   commercially	  
available	   genomic	   assays	   for	   early	   stage	   breast	   cancer	   that	   predict	   the	   likelihood	   of	  
chemotherapy	   benefit	   as	   well	   as	   recurrence	   of	   the	   disease	   [25].	   Similar	   multi-­‐gene	  
expression	   tests	   are	   required	   for	   better	   treatment	   and	   prognosis	   of	   gastric	   cancer.	  
Integration	  of	  pathway	  knowledge	  with	  genomics	  data	  can	  further	  help	  provide	  key	  targets	  






The	   long-­‐term	   goal	   of	   this	  work	   is	   to	   understand	   the	  mechanism	   by	  which	  Helicobacter	  
pylori	  mediated	  gastritis	   increases	   the	   risk	   for	  development	  of	   stomach	   cancer.	   There	  are	  
two	  objective	  of	   this	   thesis	   –	   (I)	   to	  understand	   crosstalk	  between	   inflammatory	   cytokines	  
and	  Sonic	  Hedgehog	  (SHH),	  which	  are	  activated	  during	  H.	  pylori	  infection.	  (II)	  (a)	  to	  identify	  
the	  molecular	  signature	  common	  to	  gastric	  cancer	  and	  H.	  pylori	  mediated	  atrophic	  gastritis.	  
(II)	   (b)	   drug	   repurposing	   for	   gastric	   cancer.	   These	   objectives	   are	   addressed	   using	  
computational	   approaches	  by	   the	   following	   aims.	   These	   computational	   approaches	   act	   as	  
tools	   for	  hypotheses	  generation	  and	  can	  complement	   future	  experimental	   studies	   to	  help	  
advance	   our	   current	   understanding	   of	   the	   disease.	   Each	   aim	   is	   described	   in	   detail	   in	   the	  
chapters	  3-­‐5.	  
AIM	   I:	   To	   develop	   a	   mathematical	   model	   of	   SHH	   and	   inflammatory	   cytokines	   that	   are	  
activated	  during	  H.	  pylori	  infection.	  
AIM	  II	  is	  divided	  into	  two	  sub-­‐aims:	  
I. Meta-­‐analysis	  of	  gene	  expression	  data	  to	  identify	  the	  molecular	  signature	  common	  
to	  gastric	  cancer	  and	  H.	  pylori	  mediated	  atrophic	  gastritis.	  
II. Identify	   Therapeutic	   Compounds	   that	   can	   be	   potentially	   used	   for	   Treatment	   of	  




Chapter 2: Literature Review 
2.1 Anatomy and Histology of Normal Stomach 
2.1.1 Anatomy 
The	  human	  stomach	  can	  be	  divided	  into	  different	  sections	  (Figure	  2-­‐1): 
I. Cardia:	   is	   a	   small	   space	   at	   the	   esophageal	   entrance	   to	   the	   stomach	   that	   sits	   just	  
under	  the	  diaphragm	  and	  the	  heart.	  	  
II. Fundus:	  The	  upper	  part	  of	  the	  stomach	  next	  to	  the	  cardia.	  
III. Body	  (corpus):	  The	  main	  part	  of	  the	  stomach,	  between	  the	  upper	  and	  lower	  parts.	  
IV. Antrum:	  The	  lower	  portion	  (near	  the	  intestine),	  where	  the	  food	  is	  mixed	  with	  gastric	  
juice.	  
V. Pylorus:	  The	   last	  part	  of	   the	  stomach,	  which	  acts	  as	  a	  valve	   to	  control	  emptying	  of	  
the	  stomach	  contents	  into	  the	  small	  intestine.	  
The	   first	   three	   parts	   of	   the	   stomach	   (cardia,	   fundus,	   and	   body)	   are	   sometimes	   called	  
the	  proximal	   stomach.	   Some	   cells	   in	   these	   parts	   of	   the	   stomach	  make	   acid	   and	   pepsin	   (a	  
digestive	   enzyme),	   the	   parts	   of	   the	   gastric	   juice	   that	   help	   digest	   food.	   They	   also	  make	   a	  
protein	   called	  intrinsic	   factor,	   which	   the	   body	   needs	   to	   absorb	   vitamin	   B12.	   The	   lower	   2	  








                                        
                                 
Figure 2-1. Parts of the stomach [27]. 
2.1.2 Histology 
The	  stomach	  wall	  is	  made	  up	  of	  four	  layers	  (Figure	  2-­‐2):	  
a) The	  innermost	  layer	  is	  the	  mucosa.	  The	  mucosa	  has	  3	  parts:	  epithelial	  cells,	  which	  lie	  
on	  top	  of	  a	  layer	  of	  connective	  tissue	  (the	  lamina	  propria),	  which	  is	  on	  top	  of	  a	  thin	  
layer	  of	  muscle	  (the	  muscularis	  mucosa).	  
b) Under	  the	  mucosa	  is	  a	  supporting	  layer	  called	  the	  submucosa.	  
c) Below	   this	   is	   the	  muscularis	  propria,	   a	   thick	   layer	  of	  muscle	   that	  moves	  and	  mixes	  
the	  stomach	  contents.	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d) The	  next	  two	  layers,	  the	  subserosa	  and	  the	  outermost	  serosa,	  act	  as	  wrapping	  layers	  
for	  the	  stomach	  [28].	  
	  	  	  	  	  
	  
Figure 2-2. Histology of stomach [29] 
2.2 Gastric Cancer 
2.2.1 Classification of Gastric Cancer 
Histologically,	  gastric	   tumors	   can	  be	   classified	   as	  adenocarcinoma	   (cancer	   starts	   in	  
the	  gland	  cells	  in	  the	  stomach	  lining),	  GISTs	  (Gastrointestinal	  stromal	  tumor),	  Lymphoma	  or	  
Neuroendocrine	   tumors.	   The	   most	   common	   form	   of	   stomach	   cancer	   is	  
adenocarcinoma	  [30].	  Lauren	  classified	  gastric	  adenocarcinoma	  into	  two	  histological	  types,	  
intestinal	   and	   diffuse,	   according	   to	   morphological	   features	   of	   tumor	   [31].	   Intestinal-­‐type	  
tumors	  are	  characterized	  by	  a	  corpus-­‐dominated	  gastritis	  with	  gastric	  atrophy	  and	  intestinal	  
metaplasia,	   whereas	   diffuse-­‐type	   tumors	   show	   gastritis	   throughout	   the	   stomach	   but	   no	  
atrophy	   [32].	   	   Intestinal-­‐type	   adenocarcinoma,	   progresses	   through	   a	   series	   of	   histological	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steps	   Figure	   2-­‐3	   that	   are	   initiated	   by	   the	   transition	   from	   normal	   mucosa	   to	   chronic	  
superficial	   gastritis,	   which	   then	   leads	   to	   atrophic	   gastritis	   and	   intestinal	   metaplasia,	   and	  
finally	  to	  dysplasia	  and	  adenocarcinoma	  [8].	  	  
2.2.2 Stages of Gastric Cancer 
Gastric	  cancer	  is	  routinely	  classiﬁed	  according	  to	  the	  tumor–node–metastasis	  (TNM)	  
parameters	  of	  the	  primary	  tumor,	  lymph	  nodes,	  and	  metastasis	  [33].	  Table	  2-­‐1	  summarizes	  
stage	  wise	  treatment	  options	  and	  survival	  rates	  in	  gastric	  cancer	  patients.	  
The	  TNM	  system	  for	  staging	  contains	  3	  key	  pieces	  of	  information:	  
§ T	  describes	   the	  extent	  of	   the	  primary	  tumor	   (how	  far	   it	  has	  grown	   into	   the	  wall	  of	   the	  
stomach	  and	  into	  nearby	  organs).	  
§ N	  describes	  the	  spread	  to	  nearby	  (regional)	  lymph	  nodes.	  
§ M	  indicates	  whether	  the	  cancer	  has	  metastasized	  (spread)	  to	  distant	  parts	  of	  the	  body.	  	  
Numbers	  or	   letters	  appear	  after	  T,	  N,	  and	  M	  to	  provide	  more	  details	  about	  each	  of	   these	  
factors:	  
1) The	  numbers	  0	  through	  4	  indicate	  increasing	  severity.	  
2) The	  letter	  X	  means	  “cannot	  be	  assessed”	  because	  the	  information	  is	  not	  available.	  
3) The	  letters	  “is”	  refer	  to	  carcinoma	  in	  situ,	  which	  means	  the	  tumor	  is	  only	  in	  the	  top	  layer	  






T	  categories	  of	  stomach	  cancer	  
Nearly	  all	   stomach	  cancers	  start	   in	   the	   innermost	   layer	  of	   the	  stomach	  wall	   (the	  mucosa).	  
The	  T	  category	  describes	  how	  far	  through	  the	  stomach’s	  5	  layers	  the	  cancer	  has	  invaded.	  	  
TX:	  The	  main	  (primary)	  tumor	  cannot	  be	  assessed.	  
T0:	  No	  signs	  of	  a	  main	  tumor	  can	  be	  found.	  
Tis:	  Cancer	   cells	   are	   only	   in	   the	   top	   layer	   of	   cells	   of	   the	  mucosa	   (innermost	   layer	   of	   the	  
stomach)	   and	   have	   not	   grown	   into	   deeper	   layers	   of	   tissue	   such	   as	   the	   lamina	   propria	   or	  
muscularis	  mucosa.	  This	  stage	  is	  also	  known	  as	  carcinoma	  in	  situ.	  
T1:	  The	   tumor	   has	   grown	   from	   the	   top	   layer	   of	   cells	   of	   the	  mucosa	   into	   the	   next	   layers	  
below	  such	  as	  the	  lamina	  propria,	  the	  muscularis	  mucosa,	  or	  submucosa.	  
§ T1a:	  The	  tumor	  is	  growing	  into	  the	  lamina	  propria	  or	  muscularis	  mucosa.	  
§ T1b:	  The	  tumor	  has	  grown	  through	  the	  lamina	  propria	  and	  muscularis	  mucosa	  and	  into	  
the	  submucosa.	  
T2:	  The	  tumor	  is	  growing	  into	  the	  muscularis	  propria	  layer.	  
T3:	  The	  tumor	  is	  growing	  into	  the	  subserosa	  layer.	  
T4:	  The	  tumor	  has	  grown	  into	  the	  serosa	  and	  may	  be	  growing	  into	  a	  nearby	  organ	  (spleen,	  
intestines,	  pancreas,	  kidney,	  etc.)	  or	  other	  structures	  such	  as	  major	  blood	  vessels.	  
§ T4a:	  The	  tumor	  has	  grown	  through	  the	  stomach	  wall	  into	  the	  serosa,	  but	  the	  cancer	  
hasn’t	  grown	  into	  any	  of	  the	  nearby	  organs	  or	  structures.	  





N	  categories	  of	  stomach	  cancer	  
NX:	  Nearby	  (regional)	  lymph	  nodes	  cannot	  be	  assessed.	  
N0:	  No	  spread	  to	  nearby	  lymph	  nodes.	  
N1:	  The	  cancer	  has	  spread	  to	  1	  to	  2	  nearby	  lymph	  nodes.	  
N2:	  The	  cancer	  has	  spread	  to	  3	  to	  6	  nearby	  lymph	  nodes.	  
N3:	  The	  cancer	  has	  spread	  7	  or	  more	  nearby	  lymph	  nodes.	  
§ N3a:	  The	  cancer	  has	  spread	  to	  7	  to	  15	  nearby	  lymph	  nodes.	  
§ N3b:	  The	  cancer	  has	  spread	  to	  16	  or	  more	  nearby	  lymph	  nodes.	  
	  
M	  categories	  of	  stomach	  cancer	  
M0:	  No	  distant	  metastasis	  (the	  cancer	  has	  not	  spread	  to	  distant	  organs	  or	  sites,	  such	  as	  the	  
liver,	  lungs,	  or	  brain).	  
M1:	  Distant	  metastasis	  (the	  cancer	  has	  spread	  to	  organs	  or	  lymph	  nodes	  far	  away	  from	  the	  
stomach).	  
Treatment	   of	   stomach	   cancer	   and	   survival	   rate	   depends	   to	   a	   large	   degree	   on	  where	   the	  
cancer	  started	  in	  the	  stomach	  and	  how	  far	  it	  has	  spread.	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0	   Tis,	  N0,	  M0	   Surgery	   -­‐	  
IA	   T1,	  N0,	  M0	   Surgery	   71%	  
IB	  
T1,	  N1,	  M0	   Primary:	  Surgery;	  
Secondary:	  Chemotherapy	  or	  chemoradiation	  
57%	  
T2,	  N0,	  M0	  
IIA	  
T1,	  N2,	  M0	  
Primary:	  Surgery;	  
Secondary:	  Chemotherapy	  or	  chemoradiation	  
46%	  T2,	  N1,	  M0	  
T3,	  N0,	  M0	  
IIB	  
	  
T1,	  N3,	  M0	  
Primary:	  Surgery;	  
Secondary:	  Chemotherapy	  or	  chemoradiation	  
33%	  
T2,	  N2,	  M0	  
T3,	  N1,	  M0	  
T4a,	  N0,	  M0	  
IIIA	  
	  
T2,	  N3,	  M0	  
Primary:	  Surgery;	  
Secondary:	  Chemotherapy	  or	  chemoradiation	  
20%	  T3,	  N2,	  M0	  
T4a,	  N1,	  M0	  
IIIB	  
T3,	  N3,	  M0	  
Primary:	  Surgery;	  
Secondary:	  Chemotherapy	  or	  chemoradiation	  
14%	  T4a,	  N2,	  M0	  
T4b,	  N0	  or	  N1,	  M0	  
IIIC	  
	  
T4a,	  N3,	  M0	   Primary:	  Surgery;	  
Secondary:	  Chemotherapy	  or	  chemoradiation	  
9%	  
T4b,	  N2	  or	  N3,	  M0	  
IV	   Any	  T,	  any	  N,	  M1	  
Surgery,	  Chemo	  and/or	  radiation	  therapy,	  
Targeted	  therapy	  
4%	  




2.2.3 Risk factors for Gastric Cancer 
Incidence	   rates	   for	   gastric	   cancer	   vary	  widely	   geographically,	   and,	   in	   general,	  more	  males	  
than	   females	   are	   affected	   [35].	   Although	   incidence	   rates	   of	   gastric	   cancer	   have	   been	  
declining	   worldwide	   for	   several	   decades,	   Japan,	   China,	   Eastern	   Europe,	   and	   certain	   Latin	  
America	  countries	   still	   remain	  as	  high-­‐risk	   areas	   [35].	   Several	   factors	   like	   chronic	   atrophic	  
gastritis,	  Helicobacter	  pylori	  infection,	  smoking,	  heavy	  alcohol	  use,	  and	  high	  salt	  intake	  have	  
been	   linked	   to	   increased	   risks	   for	   gastric	   cancer	   [36].	   Epidemiological	   studies	  have	   shown	  
that	   individuals	   infected	   with	  H.	   pylori	  have	   an	   increased	   risk	   of	   gastric	   adenocarcinoma	  
[37–39].	   The	   odds	   ratio	   for	   the	   relative	   risk	   for	   gastric	   carcinoma	   in	   H.	   pylori-­‐infected	  
individuals	  is	  about	  13.3	  (95%	  confidence	  interval	  (CI)	  5.3-­‐35.6)	  [40]	  to	  16.7	  (95%	  confidence	  
interval	  (CI)	  9.6–29.1)	  [41].	  The	  odds	  ratio	  further	  varies	  depending	  on	  ethnic	  background,	  
sex	  and	  age	  of	  the	  individual	  [41]	  and	  the	  strain	  of	  H.	  pylori.	  Among	  infected	  patients,	  those	  
with	   severe	   atrophy	   accompanying	   intestinal	  metaplasia,	   corpus-­‐predominant	   gastritis,	   or	  
both	  are	  at	  particularly	  high	  risk	  [37].	  	  	  
2.2.3.1 Role	  of	  Helicobacter	  pylori	  in	  gastritis	  and	  gastric	  cancer	  
H.	  pylori-­‐induced	  gastritis	  is	  associated	  with	  three	  phenotypes	  that	  correlate	  closely	  with	  
clinical	  outcome.	  
§ antrum-­‐predominant/corpus-­‐sparing	   pattern	   associated	   with	   high	   acid	   secretion	   and	  
increased	  risk	  of	  duodenal	  ulcer	  disease.	  	  
§ mild	   mixed	   antrum/corpus	   gastritis	   with	   no	   major	   effect	   on	   acid	   secretion	   and,	  
generally,	  no	  serious	  clinical	  outcome.	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§ corpus-­‐predominant	   or	   severe	   pangastritis	   pattern	   that	   is	   associated	   with	   gastric	  
atrophy,	   hypochlorhydria,	   and	   an	   increased	   risk	   of	   gastric	   cancer.	   Inhibition	   of	   gastric	  
acid	   pharmacologically	   can	   lead	   to	   a	   shift	   from	   an	   antrum-­‐predominant	   pattern	   to	   a	  
corpus-­‐predominant	  one	  with	  onset	  of	  gastric	  atrophy.	  [42]	  
H.	   pylori	  causes	   damage	   by	   initiating	   chronic	   inflammation	   in	   the	   gastric	   mucosa.	   This	  
inflammation	  is	  mediated	  by	  an	  array	  of	  pro-­‐	  and	  anti-­‐inflammatory	  cytokines	  [42].	  	  H.	  pylori	  
induced	  chronic	  gastric	  inflammation	  may	  progresses	  to	  atrophy,	  metaplasia,	  dysplasia	  and	  
ultimately	   gastric	   cancer	   [43].	   The	   bacterial	   colonization	   results	   in	   development	   of	   an	  
immune	   reaction,	   characterized	   by	   proinflammatory	   TH1	   response	   [44,45].	   Although	   the	  
immune	   response	   decreases	   H.	   pylori	   numbers	   [46],	   it	   is	   ineffective	   in	   completely	  
eradicating	   the	   bacteria	   [44]	   and	   does	   not	   provide	   resistance	   against	   reacquisition	   after	  
antimicrobial	   therapy	   [47].	   Activation	   of	   pro-­‐inflammatory	   and	   oncogenic	   transcription	  
factor	  NFkB,	  increased	  expression	  of	  epithelial	  cyclooxygenase-­‐2	  can	  potentially	  contribute	  
to	   gastric	   cancer	   [16].	   Chronic	   inflammation	   of	   gastric	   mucosa	   can	   also	   increase	   cellular	  
damage	   and	   turnover,	   thus	   promoting	   carcinogenesis	   [48,49].	   Studies	   focusing	   on	   the	  
mechanism	  by	  which	  H.	  pylori	  mediated	  inflammation	  promotes	  gastric	  cancer	  can	  help	  to	  
improve	   our	   current	   understanding	   of	   the	   disease	   and	   lead	   to	   prevention	   and	   treatment	  
strategies	   for	   gastric	   cancer.	   Overall,	   the	   risk	   of	   development	   of	   gastric	   cancer	   in	   the	  
presence	  of	  H.	  pylori	   infection	  depends	  on	  a	   variety	  of	  bacterial,	   host,	   and	  environmental	  
factors	  that	  mostly	  relate	  to	  the	  pattern	  and	  severity	  of	  gastritis	  [50].	  	  	  
	  
a) H.	  pylori	  virulence	  factors	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H.	  pylori	   infects	  50%	  of	   the	  world	  population	  but	  most	  of	   the	   carriers	  do	  not	  develop	  
gastric	  cancer	   [51].	  Cancer	  risk	   is	  associated	  with	  H.	  pylori	  strain	  differences,	   inflammatory	  
responses	  governed	  by	  host	  genetics,	  and	  specific	  interactions	  between	  host	  and	  microbial	  
determinants.	  H.	   pylori	  populations	   are	   extremely	   diverse	   [52],	   owing	   to	   point	  mutations,	  
substitutions,	   insertions	   and/or	   deletions	   in	   their	   genomes	   [53].	   Several	   genomic	   loci	  
encoding	   virulence	   factors,	   such	   as	   the	   cag	  pathogenicity	   island	   (cagPAI),	   the	   toxin	  VacA,	  
and	  the	  Bab2	  adhesin,	  have	  been	  strongly	  associated	  with	  an	   increased	  risk	  of	  developing	  
gastric	  cancer	  and	  peptic	  ulcer	  disease	  [54,55].	  	  
	  
b) Host	  susceptibility	  factors	  
It	   has	   become	   apparent	   that	   not	   only	   the	   pathogen	   but	   also	   host	   genetics	   play	   an	  
important	   role	   in	   determining	   the	   clinical	   manifestation	   of	   H.	   pylori	   infections.	   Genetic	  
polymorphisms	   in	   inﬂammatory	   genes	   tend	   to	   increase	   the	   risk	   of	   gastric	   cancer,	   as	  
demonstrated	  for	  IL-­‐1,	  a	  potent	  proinﬂammatory	  cytokine	  and	  the	  most	  prominent	  inhibitor	  
of	   gastric	   acid	   secretion	   [56].	   Reduced	   acid	   secretion	   is	   linked	   to	   corpus-­‐predominant	  
colonization	  by	  H.	   pylori	   ,	  which	   results	   in	   pangastritis	   formation	  of	   atrophic	   gastritis	   and	  
thus	   an	   increased	   risk	   of	   gastric	   cancer	   and	   gastric	   ulcer	   disease	   [57–59].	   Speciﬁc	   IL-­‐10	  
haplotypes	  lead	  to	  higher	  cytokine	  expression	  levels,	  thereby,	  shifting	  the	  balance	  towards	  
an	   anti-­‐inﬂammatory	   host	   cell	   [60,61];	   this	   is	   associated	   with	   the	   colonization	   of	   more	  
virulent	  H.	  pylori	  strains	  [62].	  However,	  speciﬁc	  IL-­‐10	  haplotypes	  actually	  induce	  lower	  IL-­‐10	  
expression	  levels,	  favouring	  pro-­‐inﬂammatory	  responses	  and	  an	  associated	  increased	  risk	  of	  
gastric	   cancer	   [63].	   Analysis	   of	   high-­‐throughput	   gene	   expression	   from	   H.	   pylori	   infected	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stomach	  tissues	  can	  help	  to	  identify	  more	  of	  such	  genes	  that	  influence	  the	  final	  outcome	  of	  
the	  disease.	   These	  genes	  may	   serve	  as	   candidate	  biomarkers	  and	  can	  be	  used	   for	   several	  
applications	  such	  as	   for	  diagnosis,	  prognosis,	   sub-­‐classification	  of	   the	  disease,	   response	   to	  
specific	  drugs	  and	  as	  potential	  drug	  targets.	  	  
	  
c) Molecular	  Mimicry	  	  
One	  of	  the	  mechanisms	  for	  the	  failure	  of	  host’s	  immune	  system	  in	  eliminating	  H.	  pylori	  
includes	  the	  ability	  of	  the	  bacteria	  to	  evade	  host	  adaptive	  and	  innate	  responses	  by	  frequent	  
antigenic	   variation,	   and	   host	   antigen	   mimicry	   [16,64].	   Molecular	   mimicry	   refers	   to	   a	  
condition	  where	  microbial	  antigen	  can	   include	  an	  epitope	   that	   is	   structurally	   similar	   to	  an	  
auto-­‐antigen	  epitope	   [65].	  H.	  pylori	   infection	  can	  mediate	   the	  autoimmune	  destruction	  of	  
the	   gastric	   corpus	   mucosa	   and	   lead	   to	   autoimmune	   gastritis	   (AIG)	   or	   pernicious	   anemia	  















2.2.4 Gastric Cancer Diagnosis 
	  
2.2.4.1 Symptoms	  
The	  physical	   symptoms	  of	  gastric	  cancer,	  which	   include	  poor	  appetite,	  weight	   loss,	  
abdominal	  pain,	  heartburn,	  nausea,	  and	  anemia,	  are	  not	  specific	  to	  gastric	  cancer	  alone	  and	  
are	  often	  associated	  with	  stomach	  virus	  or	  ulcer	  [67].	  	  	  
	  
2.2.4.2 Diagnosis	  
The	  initial	  diagnosis	  of	  gastric	  carcinoma	  often	  is	  delayed	  because	  up	  to	  80	  percent	  
of	   patients	   are	   asymptomatic	   during	   the	   early	   stages	   of	   stomach	   cancer	   [68].	  In	   Japan,	   a	  
higher	  incidence	  of	  adenocarcinoma	  and	  rigorous	  screening	  processes	  have	  led	  to	  a	  greater	  
number	  of	  cases	  of	  gastric	  cancer	  being	  detected	  in	  an	  early	  stage	  (i.e.,	  when	  limited	  to	  the	  
mucosa	   and	   submucosa,	   with	   or	   without	   lymph	   node	   involvement)	   [17].	  	   The	   diagnostic	  
techniques	   include	   Esophagogastroduodenoscopy	   (EGD),	   Endoscopic	   ultrasonography,	  
computed	  tomographic	  (CT)	  scanning	  [17].	  
	  
2.2.4.3 Genetic	  Screening	  
Hereditary	  diffuse	  gastric	  cancer	  (HDGC)	  is	  an	  autosomal	  dominant	  genetic	  condition	  
associated	  with	   an	   increased	   risk	  of	  gastric	   cancer.	  It	   is	   associated	  most	   frequently	  with	   a	  
heterozygous	  germline	  mutation	   in	  CDH1,	   the	  gene	  that	  encodes	  E-­‐cadherin.	  CDH1	  has	  an	  
essential	   role	   in	  cell–cell	  adhesion	   [69].	  A	  mutation	   in	   the	  CDH1	  gene	   increases	   the	  risk	  of	  
developing	   gastric	   cancer	   and	   other	   cancers	   associated	   with	   HDGC.	   Not	   everyone	   who	  
inherits	  a	  gene	  mutation	  for	  HDGC	  will	  develop	  cancer.	   In	  people	  who	  have	  a	  mutation	   in	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the	  CDH1	  gene,	   the	   lifetime	   risk	   for	   advanced	   diffuse	   gastric	   cancer	   is	   estimated	   to	   be	  
greater	  than	  80%	  for	  men	  and	  women	  by	  age	  80.	  	  Screening	  for	  stomach	  cancer	  is	  suggested	  
for	   people	   known	   to	   be	   at	   risk	   for	   HDGC	   [70,71].	   High-­‐throughput	   analysis	   of	   gene	  
expression	   data	   from	   patient	   and	   healthy	   population	   can	   help	   to	   improve	   our	   current	  
understanding	   of	   the	  molecular	   profile	   of	   gastric	   cancer	   and	   identify	   potential	   diagnostic	  
biomarkers	  and	  candidate	  drug	  targets.	  	  
2.2.5 Currently Available Therapy for Gastric Cancer 
There	  are	  three	  main	  modes	  of	  therapy	  for	  the	  treatment	  of	  gastric	  cancer	  –	  surgery,	  
radiation	   and	   chemotherapy.	   Treatment	   with	   surgery	   alone	   is	   not	   very	   promising	   in	  
improving	  the	  survival	  rate	  [17].	  Gastric	  cancer	  has	  not	  been	  shown	  to	  respond	  successfully	  
to	   radiation	   alone.	   Chemotherapy	   has	   demonstrated	   limited	   success	   with	   multi-­‐drug	  
regimens	   [72].	   The	   common	   drugs	   approved	   for	   gastric	   cancer	   include	   fluorouracil,	  
ramucirumab,	  docetaxel,	  trastuzumab,	  mitomycin	  C,	  doxorubicin	  [73].	  	  
Since,	  chemotherapeutic	  drugs	  target	  rapidly	  dividing	  cells,	  which	  includes	  both	  cancer	  
cells	   and	   certain	   normal	   tissues,	   they	   are	   associated	   with	   severe	   adverse	   effects	   and	  
toxicities.	  Although	  traditional	  cytotoxic	  chemotherapy	  remains	  the	  treatment	  of	  choice	  for	  
many	  malignancies,	  with	  recent	  advancement	   in	  molecular	  cancer	  biology,	   targeted-­‐based	  
drugs	  have	  emerged	  as	  a	  component	  of	  treatment	  for	  many	  types	  of	  cancer,	  including	  that	  
of	  breast,	  colorectal,	  lung,	  pancreatic	  cancers,	  lymphoma,	  leukemia,	  and	  multiple	  myeloma	  
[20].	   Targeted	   therapy	   aims	   to	   act	   on	   a	   specific	   target	   or	   biologic	   pathway	   that,	   when	  
inactivated,	  causes	  regression	  or	  destruction	  of	  the	  malignant	  process	  [74].	  Currently,	  there	  
are	  only	  two	  FDA	  approved	  target	  based	  drugs	  for	  gastric	  cancer	  treatment	  –	  Trastuzumab	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(targeting	  HER2)	  [21]	  and	  Ramucirumab	  (targeting	  VEGF)	  [22].	  Trastuzumab,	  which	  binds	  to	  
HER2	   receptors,	   was	   originally	   approved	   by	   FDA	   for	   breast	   cancer	   treatment	   in	   1998.	  
Overexpression	   and/or	   amplification	   of	   HER2	   has	   been	   found	   in	   about	   20–30%	   of	   breast	  
cancers	   [75],	   in	   >20%	   of	   gastric	   cancers	   and	   in	   33%	   of	   gastroesophageal	   junction	   (GEJ)	  
adenocarcinoma	  [76].	  	  In	  2010,	  FDA	  granted	  approval	  for	  trastuzumab,	  in	  combination	  with	  
cisplatin	  and	  a	  fluoropyrimidine	  (either	  capecitabine	  or	  5-­‐fluorouracil),	  for	  the	  treatment	  of	  
patients	   with	   HER2-­‐overexpressing	   metastatic	   gastric	  or	   gastroesophageal	   junction	   (GEJ)	  
adenocarcinoma	  who	   have	   not	   received	   prior	   treatment	   for	  metastatic	   disease	   [77].	   It	   is	  
now	  recommended	  that	  all	  patients	  with	  gastric	  cancer	  should	  have	  their	  tumors	  tested	  for	  
HER2	   status	  at	   the	   time	  of	   initial	  diagnosis.	   Studies	   focusing	  on	  molecular	  profiling	  of	   the	  
gastric	  tumors	  can	  help	  to	  identify	  specific	  biomarkers	  like	  HER2	  and	  help	  in	  selecting	  drugs	  
that	  target	  those	  biomarkers.	  	  	  
	  
2.3 Drug Repurposing: Finding new uses of old drugs  
Development	   of	   a	   new	   drug	   usually	   takes	   around	   10	   years	   and	   can	   cost	   of	   several	  
billion	  dollars	  [23].	  One	  of	  the	  major	  reasons	  for	  this	  extraordinary	  cost	  is	  high	  rate	  of	  failure	  
in	  the	  preclinical	  and	  clinical	  phase.	  Only	  one	  out	  of	  ten	  new	  drugs	  in	  clinical	  trials	  reach	  the	  
FDA	  approval	  stage	  [78].	  One	  of	  the	  approaches	  to	  reduce	  the	  high	  cost	  and	  time	  associated	  
with	  drug	  discovery	  is	  through	  repurposing	  of	  drugs	  already	  approved	  for	  other	  diseases.	  A	  
key	  advantage	  of	  drug	  repurposing	  is	  the	  established	  clinical	  safety	  of	  the	  drug.	  	  
Drug	   repurposing	   strategy	   has	   been	   proven	   to	   be	   therapeutically	   useful	   in	   several	  
diseases.	  A	  well-­‐known	  example	  of	  a	  successful	  repurposed	  drug	  is	  Sildenafil	  (Viagra),	  which	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was	   originally	   developed	   to	   treat	   erectile	   dysfunction.	   Later	   it	   was	   discovered	   that	   the	  
vasodilatory	   effects	   of	   sildenafil	   also	   help	   reduce	   symptoms	   of	  pulmonary	   arterial	  
hypertension	   (PAH)	   and	   FDA	   subsequently	   approved	   the	   drug	   for	   treatment	   of	   PAH	   [79].	  
Raloxifene	  was	   first	   used	   to	   prevent	  osteoporosis	  (bone	   loss)	   in	   postmenopausal	   women.	  
Raloxifene	   is	   now	   used	   for	   the	   reduction	   in	   the	   incidence	   of	   invasive	   breast	   cancer	   in	  
postmenopausal	  women	  with	  osteoporosis	  or	  have	  a	  high	  risk	  for	  developing	  breast	  cancer	  
[80].	  In	  2010,	  FDA	  approved	  use	  of	  a	  breast	  cancer	  drug	  -­‐	  trastuzumab	  with	  chemotherapy	  
for	  treatment	  for	  metastatic	  stomach	  cancer	  in	  HER2	  positive	  patients	  [81].	  Identification	  of	  
existing	   drugs	   that	   have	   potential	   in	   treatment	   of	   gastric	   cancer	   can	   help	   improve	   the	  
survival	  rate	  for	  the	  disease.	  	  Chapter	  5	  explains	  in	  detail	  how	  we	  used	  genomics	  data	  and	  
Broad	   Institute’s	  Connectivity	  Map	   to	   identify	   FDA	  approved	  drugs	  and	  nondrug	  bioactive	  
compounds	  that	  can	  be	  potentially	  used	  for	  treatment	  of	  gastric	  cancer.	  
2.4 Mathematical Modeling 
2.4.1 Why mathematical models? 
To	   understand	   complex	   biological	   systems,	   in	   addition	   to	   the	   identification	   and	  
characterization	   of	   the	   individual	   components,	   it	   is	   also	   important	   to	   understand	   the	  
interactions	   between	   molecules	   and	   pathways.	   However,	   this	   understanding	   is	   often	  
difficult	  to	  achieve	  experimentally	  due	  to	  high	  cost	  and	  time	  associated	  with	  such	  studies.	  
Mathematical	  models	  are	  abstractions	  of	  complex	  biological	  processes	  and	  allow	  prediction	  
of	  the	  system	  behavior	  (under	  given	  condition).	  Mathematical	  models	  enable	  and	  facilitate	  
studies	  aimed	  at	   investigating	   the	  mechanism	  through	  which	  different	  components	  of	   the	  
37	  
	  
system	   are	   interlinked	   and	   how	   disruptions	   of	   these	   links	   may	   contribute	   to	   the	  
development	   of	   disease	   [82].	   Investigation	   of	   a	   signaling	   network’s	   positive	   and	   negative	  
feedback	  loops	  can	  give	  insight	  into	  the	  network’s	  behavior,	  and	  identify	  important	  system	  
properties	  such	  as	  multi-­‐stability,	  excitability,	  and	  oscillations	  [83].	  Dynamic	  models	  identify	  
emergent	   patterns	   of	   the	   system	   that	   may	   be	   non-­‐observable	   and	   non-­‐intuitive	   when	  
individual	  components	  of	  the	  network	  are	  studied	  in	  isolation.	  For	  example,	  Lev	  Bar-­‐Or	  et	  al.	  
developed	   a	   mathematical	   model	   suggesting	   that,	   given	   a	   sufficient	   time	   delay	   for	   p53-­‐
induced	  Mdm2	  transcription,	  the	  core	  p53	  circuit	  can	  give	  rise	  to	  oscillations.	  To	  model	  this	  
behavior,	   the	   authors	   created	   a	   set	   of	   Ordinary	   Differential	   Equations	   to	   describe	   the	  
system	  and	  added	  a	  hypothetical	  intermediate	  that	  directs	  Mdm2	  transcription	  with	  kinetics	  
governed	  by	  a	  Hill	  function.	  Using	  immunoblots,	  they	  verified	  that	  the	  levels	  of	  Mdm2	  and	  
p53	   oscillate	   in	   response	   to	   DNA	   damage–inducing	   irradiation.	   Although	   the	   model	  
parameters	  were	  estimated	  rather	  than	  measured	  or	  ﬁt	  to	  experimental	  data,	  Lev	  Bar-­‐Or	  et	  
al.	  were	  able	  to	   infer	  qualitative	  behaviors	  such	  as	  the	  broadening	  of	  the	  p53	  response	  to	  
weaker	   DNA	   damage	   signals	   (Lev	   Bar-­‐Or	   et	   al.,	   2000	   ;	   Hughey,	   Lee,	   &	   Covert,	   2009).	  
Although	   in-­‐silico	   models	   cannot	   replace	   laboratory	   experiments,	   simulations	   enable	   the	  
exploration	  of	  many	  different	  aspects	  of	  the	  system’s	  behavior	  at	  low	  cost	  and	  in	  much	  less	  
time.	  	  
2.4.2 Modeling biology using Ordinary Differential Equations 
Different	   approaches	   have	   been	   employed	   in	   order	   to	   model	   the	   dynamics	   of	  
biological	   systems,	   for	   example:	   Boolean,	   Ordinary	   Differential	   Equations,	   Flux	   Balance	  
Analysis,	   stochastic,	   cellular-­‐automata	   [86].	   The	   choice	  of	  modeling	   approach	  depends	  on	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the	   goal	   of	   the	   study.	   	   In	   Boolean	   modeling,	   a	   gene’s	   expression	   or	   protein	   level	   is	  
represented	   by	   binary	   code	   -­‐	   1	   for	   active	   (on)	   or	   0	   for	   inactive	   (off)	   and	   hence	   that	   its	  
products	  are	  present	  or	  absent.	  Although	  Boolean	  networks	  are	  efficient	  for	  analyzing	  large	  
regulatory	  networks,	  in	  Boolean	  formalism,	  a	  gene	  is	  considered	  to	  be	  either	  on	  or	  off,	  and	  
intermediate	  expression	   levels	  are	   ignored.	  Also,	   transitions	  between	  the	  activation	  states	  
of	   the	  genes	  are	  assumed	  to	  occur	  synchronously.	  However,	   in	  many	  biological	  processes,	  
transitions	  may	  not	  take	  place	  simultaneously	  [86].	  
Kinetic	  ordinary	  differential	  equation	  (ODE),	  assumes	  that	  molecular	  concentrations	  
are	   continuous	   	  (it	   ignores	   the	   discrete	   nature	   of	   molecules),	   that	   reactions	   occur	   in	   a	  
homogeneous,	   well-­‐stirred	   volume	   and	   that	   these	   reactions	   occur	   in	   a	   deterministic	  
manner.	  In	  an	  ODE	  model,	  a	  reaction	  network	  is	  expressed	  as	  a	  set	  of	  differential	  equations	  
with	  one	  equation	  per	  chemical	  and	  with	  terms	  that	  represent	  the	  reactions	  [87].	  However,	  
a	  key	  challenge	  with	  ODE	  modeling	  is	  the	  lack	  of	  knowledge	  about	  kinetic	  parameters.	  The	  
rate	  of	  change	  of	  product	  P	  with	  respect	  to	  time	  can	  be	  represented	  by	  following	  equation:	  	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  	  	  	   	   	  
	  	  	  	  	  	  	  	  	  	  	  	  	   	  
Stochastic	  models	   incorporate	   randomness	   and	  may	   be	   closer	   to	   reality	   than	   continuous	  
and	   deterministic	   approaches,	   however	   they	   are	   numerically	   more	   difficult	   to	   solve	   and	  
computationally	   expensive.	   Flux	   Balance	   Analysis	   is	   often	   used	   for	   studying	   metabolic	  
networks	  and	   it	   is	  most	  appropriate	   for	   identifying	  optimal	   fluxes	   for	  biomass	  production.	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Cellular	  automata	  can	  be	  used	  to	  study	  change	  in	  spatial	  patterns	  or	  movement	  of	  cells	  over	  
time	  [87].	  	  
2.4.3 Using Eigenvalues to determine system’s stability 
Stability	   of	   an	  ODE	   (ordinary	   differential	   equations)	   system	   can	   be	   determined	   by	  
eigenvalues	  derived	  from	  Jacobian	  matrix	  of	  that	  system.	  The	  Jacobian	  matrix	  summarizes	  
how	   every	   variable	   changes	   with	   each	   of	   the	   other	   variables	   at	   a	   given	   point.	  
Mathematically,	   it	   is	   always	   a	   square	  matrix	   (i.e.,	   number	   of	   rows	   of	  matrix	   =	   number	   of	  
columns	  of	  matrix).	  The	  eigenvalues	  (λ)	  are	  complex	  numbers	  (of	  form	  a	  +	  bi)	  with	  real	  and	  
imaginary	  part	  and	  inform	  about	  stability	  of	  the	  system.	  The	  imaginary	  part	  of	  an	  eigenvalue	  
determines	  if	  the	  system	  will	  oscillate	  while	  the	  real	  part	  determines	  whether	  the	  amplitude	  
of	   oscillations	   increases	   or	   decreases	  with	   time.	   Table	   2-­‐2	   and	   Figure	   2-­‐4	   summarize	   the	  
different	  forms	  of	  eigenvalues	  and	  its	  impact	  on	  stability	  of	  the	  system.	  When	  λ	  has	  negative	  
real	  part	  and	  zero	  imaginary	  part,	  the	  system	  decays	  exponentially;	  when	  all	  λ	  are	  real,	  and	  
at	   least	  one	   is	  positive,	   the	  system	  increases	  exponentially.	   If	  λ	  has	  negative	  real	  part	  and	  
nonzero	  imaginary	  part,	  the	  system	  exhibits	  damped	  oscillations;	  if	  λ	  has	  zero	  real	  part	  and	  
nonzero	   imaginary	   part,	   the	   system	   shows	   sustained	   oscillations;	   for	   λ	   with	   at	   least	   one	  
positive	   real	   part	   and	   some	   imaginary	   parts,	   the	   system	   will	   oscillate	   with	   increasing	  





Eigenvalue	  (λ)	  Type	   Mathematical	  form	  for	  λ	   System’s	  Stability	   System’s	  Behavior	  
All	  λ	  are	  real	  and	  
negative	  
-­‐a	  +	  0i	   Stable	   Exponential	  decay	  
All	  λ	  are	  real	  and	  positive	   +a	  +	  0i	   Unstable	   Exponential	  increase	  
All	  λ	  have	  negative	  real	  
parts,	  some	  imaginary	  
parts	  
-­‐a	  +	  bi	   Stable	   Damped	  oscillation	  
At	  least	  one	  λ	  has	  
positive	  real	  parts,	  some	  
imaginary	  parts	  
+a	  +	  bi	   Unstable	   Increase	  with	  oscillation	  
All	  λ	  have	  zero	  real	  parts	  
and	  nonzero	  imaginary	  
parts	  
0	  +	  bi	   Unstable	   Undamped	  oscillation	  
Table 2-2. Determination of system’s behavior by eigenvalues derived from Jacobian matrix of system.       
	  
                                    
Figure 2-4. Determination of system’s behavior by eigenvalues derived from Jacobian matrix of system 




Chapter 3: Mathematical model for studying Helicobacter pylori 
mediated inflammation in host gastric tissue. 
“A mathematical model is neither a hypothesis nor a theory. Unlike scientific 
hypotheses, a model is not verifiable directly by an experiment. For all models are 
both true and false.... The validation of a model is not that it is "true" but that it 
generates good testable hypothesis relevant to important problems.” 
- R. Levins, Am. Scientist 54:421-31, 1966 
 
3.1 Synopsis 
Helicobacter	   pylori	   infection	   of	   gastric	   tissue	   results	   in	   an	   immune	   response	  
dominated	  by	  Th1	  cytokines	  and	  has	  also	  been	  linked	  with	  deregulation	  of	  Sonic	  Hedgehog	  
(SHH)	  signaling	  pathway	  in	  gastric	  tissue.	  However,	  interactions	  between	  the	  cytokines	  and	  
SHH	   during	   H.	   pylori	   infection	   are	   not	   well	   understood.	   Here,	   we	   use	   mathematical	  
modeling	  aided	  by	  restraints	  of	  experimental	  data	  to	  understand	  the	  temporal	  behavior	  of	  
H.	  pylori	  activated	  cytokine	  circuit.	  Statistical	  analysis	  of	  qPCR	  data	  from	  uninfected	  and	  H.	  
pylori	   infected	  wild-­‐type	  and	  parietal	  cell-­‐specific	  SHH	  knockout	  (PC-­‐SHHKO)	  mice	  for	  day	  7	  
and	   day	   180	   suggest	   role	   of	   SHH	   in	   cytokine	   regulation.	   The	   experimentally	   observed	  
changes	   are	   further	   investigated	   using	   a	   mathematical	   model	   that	   examines	   dynamic	  
crosstalks	   among	  pro-­‐inflammatory	   (IL1β,	   IL-­‐12,	   IFNγ,	  MIP-­‐2)	   cytokines,	   anti-­‐inflammatory	  
(IL-­‐10)	   cytokines	   and	   SHH	   during	   H.	   pylori	   infection.	   	   Analysis	   of	   the	   resulting	   model	  
demonstrates	   that	   circuitry,	   as	   currently	   known,	   is	   inadequate	   for	   explaining	   of	   the	  
experimental	   observations,	   suggesting	   the	   need	   for	   additional	   specific	   regulatory	  
interactions.	  A	  key	  advantage	  of	  a	   computational	  model	   is	   the	  ability	   to	  propose	  putative	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circuit	   models	   for	   in-­‐silico	   experimentation.	   We	   use	   this	   approach	   to	   propose	   a	  
parsimonious	   model	   that	   incorporates	   crosstalks	   between	   NFĸB,	   SHH,	   IL-­‐1β	   and	   IL-­‐10,	  
resulting	  in	  a	  feedback	  loop	  capable	  of	  exhibiting	  cyclic	  behavior.	  Separately,	  we	  show	  that	  
analysis	  of	  an	  independent	  time-­‐series	  microarray	  data	  for	  IL-­‐1β,	  IFNγ	  and	  IL-­‐10	  in	  mock	  and	  
H.	  pylori	   infected	  mice	  further	  supports	  the	  proposed	  hypothesis	  that	  these	  cytokines	  may	  
follow	   a	   cyclic	   trend.	   Predictions	   from	   the	   in-­‐silico	   model	   provide	   useful	   insights	   for	  
generating	  new	  hypotheses	  and	  design	  of	  subsequent	  experimental	  studies.	  
The	  work	  described	  in	  this	  chapter	  is	  published	  as	  “Crosstalks	  between	  Cytokines	  and	  Sonic	  
Hedgehog	  in	  Helicobacter	  pylori	  Infection:	  A	  Mathematical	  Model.”	  	  [91].	  	  
3.2 Background 
Helicobacter	  pylori	  is	  a	  significant	  risk	  factor	  for	  atrophic	  gastritis	  [92,93],	  gastric	  ulcer	  
[93,94]	   and	   gastric	   cancer	   [38,93,94].	   	   The	  host	   cell	   detects	   the	   presence	  of	   bacteria	   and	  
produces	  an	   immune	  response	  to	  eliminate	  the	  bacteria.	  The	   final	  outcome	  depends	  on	  a	  
balance	   between	   pro-­‐inflammatory	   and	   anti-­‐inflammatory	   cytokines	   produced	   during	   H.	  
pylori	   infection	   [60,95].	  A	   strong	  pro-­‐inflammatory	   response	  may	  allow	  eradication	  of	   the	  
bacteria	   however	   at	   a	   cost	   of	   increased	   risk	   for	   gastritis	   [96]	   while	   anti-­‐inflammatory	  
cytokines	   may	   protect	   against	   gastritis,	   but	   H.	   pylori	   may	   continue	   to	   persist	   [97,98].	  
Another	  gene	  that	  has	  been	  recently	  identified	  to	  play	  an	  important	  role	  in	  pathogenesis	  of	  
chronic	  H.	  pylori	  infection	  [99,100]	  and	  gastric	  cancer	  [101–104]	  	  is	  sonic	  hedgehog	  (SHH).	  In	  
both	  human	  and	  mouse	  stomachs,	   it	   is	  expressed	  in	  the	  parietal	  cells	  [105].	  Under	  normal	  
conditions,	   SHH	   regulates	   differentiation	   of	   the	   gastric	   epithelium	   [105,106]	   and	   T-­‐cell	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[107,108].	  During	   chronic	  H.	  pylori	   infection,	   SHH-­‐dependent	  proliferation	  of	  parietal	   cells	  
plays	  a	  key	  role	  in	  gastric	  mucosal	  repair	  [99,109].	  It	  has	  been	  shown	  that	  SHH	  is	  involved	  in	  
early	   immune	   response	   to	   H.	   pylori	   [110,111]	   and	   act	   as	   a	   monocyte/macrophage	  
chemoattractant	  during	  H.	  pylori	  infection	  [111].	  Schumacher	  et	  al	  have	  shown	  that	  parietal	  
cell-­‐specific	  SHH	  knock-­‐out	  (PC-­‐SHHKO)	  mice	  failed	  to	  develop	  gastritis,	  even	  after	  6	  months	  
of	  H.	  pylori	  infection	  in	  contrast	  to	  infected	  control	  group	  (WT)	  which	  developed	  significant	  
inflammatory	   response	   [111].	   Another	   group	   has	   shown	   that	   overexpression	   of	   ShhWT	  
induced	  gastritis	  while	  CMV-­‐ShhF200H	  mice	   (carrying	  mutant	  SHH)	  did	  not	  develop	  gastritis.	  
They	   also	   reported	   that	   SHH	  overexpression	   exacerbated	   the	   histologic	   severity	   observed	  
with	  Helicobacter	  felis	  infection	  and	  increased	  the	  amount	  of	  myeloid	  cells	  recruited	  to	  the	  
inflamed	  stomach	  as	  compared	  to	  that	  in	  non-­‐transgenic	  mice	  [110].	  	  
Although	   recent	   studies	   have	   highlighted	   the	   immunoregulatory	   role	   of	   SHH	   in	  
stomach	   [110,111],	   a	   model	   studying	   temporal	   relationship	   between	   SHH	   and	   cytokines	  
activated	  during	  H.	  pylori	  infection	  is	  still	  lacking,	  and	  it	  is	  unexplored	  what	  effect	  SHH	  may	  
have	  in	  the	  context	  of	  regulating	  cytokine	  expression	  in	  the	  H.	  pylori	  infected	  stomach.	  Such	  
temporal	  studies	  are	  not	  readily	  amenable	  to	  experimental	  approaches	  because	  of	  high	  cost	  
and	  time	  associated	  with	   time	  series	   in-­‐vivo	  experiments.	   In-­‐vitro	  experiments	  of	   immune	  
responses	   often	   face	   experimental	   limitations	   –	   for	   example,	   lack	   of	   a	   host	   immune	   cell	  
response.	  Mathematical	  modeling	  is	  a	  powerful	  technique	  to	  complement	  such	  studies	  as	  it	  
allows	   predicting	   dynamic	   behavior	   of	   the	   system	   under	   various	   perturbations	   and	  
generating	   new	   hypotheses.	   Currently,	   there	   are	   only	   a	   handful	   of	  mathematical	  models	  
that	   study	   the	  H.	   pylori	   -­‐	   host	   immune	   response,	   and	   though	   they	   provide	   high-­‐level	   or	  




To	   develop	   a	   mathematical	   model	   of	   Sonic	   Hedgehog	   and	   inflammatory	   cytokines,	  
which	  are	  activated	  during	  Helicobacter	  pylori	  infection.	  
3.4 Methods 
3.4.1 Animal Model 
qPCR	  (Quantitative	  real-­‐time	  Polymerase	  Chain	  Reaction)	  data	  from	  uninfected	  and	  
H.	  pylori	  infected	  mice,	  was	  received	  from	  Zavros	  lab.	  Briefly,	  the	  mouse	  model	  with	  parietal	  
cell-­‐specific	   deletion	   of	   SHH	   (PC-­‐SHHKO)	   was	   generated	   as	   previously	   described	   (C57Bl/6,	  
129/Sv	  background)	   [106]	   and	  HKCre	  mice	   expressing	  Cre	   transgene	  under	   the	   control	   of	  
H+,K+-­‐adenosine	  triphosphatase	  (ATPase)	  β	  subunit	  promoter	  (C57Bl/6,	  FVB/N	  background)	  
were	   used	   as	   control	   [111].	   HKCre	   (WT)	   and	   PC-­‐SHHKO	   mice,	   aged	   8	   weeks	   were	   either	  
infected	  with	  H.	  pylori	  or	  left	  uninfected.	  The	  uninfected	  group	  received	  200	  µl	  of	  Brucella	  
broth	  over	  3	  consecutive	  days	  whereas	  the	  infected	  group	  was	  inoculated	  with	  108	  H.	  pylori	  
SS1	   (Sydney	   strain	  1)	  bacteria	  per	  200	  µl	   of	  Brucella	  broth	  over	  3	   consecutive	  days.	  Mice	  
(n=3-­‐4	  per	  group)	  were	  sacrificed	  on	  day	  7	  and	  180	  post-­‐infection	  and	  levels	  of	  gastric	  SHH	  
and	   cytokines	   were	   assayed	   by	   qPCR.	   H.	   pylori	   colonization	   as	   measured	   by	   bacterial	  
cultures	  and	  analysis	  of	  CFU/g	  Tissue	  (colony-­‐forming	  units	  per	  gram	  tissue)	  for	  WT	  and	  PC-­‐
SHHKO	  infected	  mouse	  stomachs	  were	  shown	  to	  be	  equivalent	  [111].	  Total	  RNA	  was	  isolated	  
from	  stomachs	  of	  uninfected	  and	  infected	  WT	  and	  PC-­‐SHHKO	  mice.	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3.4.2 Interaction Map 
An	  interaction	  map	  -­‐	  a	  topological	  network	  of	  signaling	  pathways,	  activated	  by	  H.	  pylori,	  
was	  manually	  curated	  from	  literature	  [116,117]	  (Figure	  3-­‐1).	  H.	  pylori	  virulence	  factors	  like	  
CagA	   [43,118,119],	  VacA	   [118]	   and	  PGN	   [118]	   activate	   a	   cascade	  of	   signaling	  pathways	   in	  
epithelial	   cells	   of	   host	   stomach.	   Virulence	   factor	   CagA	   	  (cytotoxin-­‐associated	   gene	   A)	  
activates	   ERK	   [43,109,120]	   and	   AKT	   [121]	   pathways	   which	   further	   stimulate	   nuclear	  
translocation	   of	   NFĸB	   [121–123].	   Effector	   molecule	   PGN	   (peptidogylcan)	   is	   sensed	   by	  
intracellular	  receptor	  NOD1	  (nucleotide-­‐binding	  oligomerization	  domain	  1)	  [109,118]	  which	  
activates	   NFĸB	   [109,118,119,124],	   ERK,	   p38	   and	   AP-­‐1	   [124].	   Protein	   VacA	   (Vacuolating	  
cytotoxin	  A)	  also	  stimulates	  ERK	  and	  p38	  pathways	  [125]	  which	  activate	  transcription	  factor	  
AP-­‐1	   [43,126–128].	   Both	   NFĸB	   and	   AP-­‐1	   positively	   regulate	   chemokine	   IL-­‐8/MIP-­‐2	  
transcription	  [43,119,129].	  (MIP-­‐2	  is	  a	  functional	  homolog	  of	  human	  IL-­‐8	  in	  mouse	  [130]).	  H.	  
pylori	  colonization	  of	  gastric	  epithelium	  eventually	  leads	  to	  recruitment	  of	  monocytes	  which	  
secrete	  pro-­‐inflammatory	  cytokines	  like	  IL-­‐12,	  IL-­‐1β,	  TNFα,	  IL6	  [131–133]	  and	  IL8	  [134,135].	  
IL-­‐12	   and	   other	  H.	   pylori	   antigens	   synergistically	   stimulates	   release	   of	   IFNγ	   from	   natural	  
killer	  cells	  [133,136–138].	  SHH,	  a	  crucial	  player	  in	  early	  immune	  response	  to	  H.	  pylori	  [111]	  
has	   been	   reported	   as	   a	   putative	   target	   of	   NFĸB	   in	   gastric	   [139]	   and	   pancreatic	   cancer	  
[140,141].	  Interestingly,	  Waghray	  et	  al	  have	  shown	  that	  IL-­‐1β	  suppresses	  SHH	  expression	  in	  
parietal	   cells	   by	   inhibiting	   acid	   secretion	   [142].	   Along	   with	   the	   activation	   of	   pro-­‐
inflammatory	   cytokines,	   IL-­‐10,	   an	   anti-­‐inflammatory	   cytokine	   is	   also	   produced	   during	   H.	  
pylori	   infection	   [131,138,143].	   IL-­‐10	   has	   been	   reported	   to	   inhibit	   NFĸB	   activity,	   and	  
subsequently	  IL-­‐8	  transcription	  in	  gastric	  epithelial	  cells	  during	  H.	  pylori	  infection	  [144]	  and	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also	   in	  macrophage	   [145]	   and	   T-­‐cells	   [146].	   In	   summary,	   different	   virulence	   factors	   of	   H.	  
pylori	  activate	  various	  signaling	  pathways	  in	  the	  stomach	  tissue	  leading	  to	  increased	  activity	  
or	  expression	  of	  NFĸB,	   chemokines	  and	   cytokines	   [147,148].	   The	   severity	  of	   inflammation	  
and	  exact	  details	  of	  signaling	  pathways	  described	  above	  can	  vary	  depending	  on	  the	  strain	  of	  
H.	  pylori	  and	  strain	  of	  mice	  used	  in	  the	  experiment	  [149,150].	  	  
	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Figure 3-1. Interaction Map of signaling pathways activated in host stomach in response to H. pylori.  
H. pylori virulence factors (CagA, VacA and PGN, shown in orange) activate cascade of signaling pathways in 
host gastric epithelium that leads to nuclear translocation of NFĸB. NFĸB further activates IL8/MIP-2 and SHH. 
Immune response to the bacteria involves recruitment of monocytes to gastric epithelium where they secrete 
cytokines like IL-12, IL-1β, TNFα, IL6, IL10 and IL8. Blue arrows show activation while red lines represent 
inhibition. The network was built using Cytoscape using information based on current literature. However, the 





3.4.3 Statistical Analysis 
For	  each	  sample,	  dCT	  value	  for	  target	  gene	  was	  calculated	  by	  subtracting	  CT	  value	  of	  
calibrator	  gene	  (GAPDH)	  from	  CT	  value	  of	  target	  gene.	  To	  test	  if	  expression	  of	  target	  gene	  in	  
gastric	  mucosa	  was	  affected	  by	  H.	  pylori	  and	  if	  this	  effect	  was	  same	  in	  all	  genotypes,	  a	  two-­‐
way	  ANOVA	  (Analysis	  of	  variance)	  test	  was	  performed,	  comparing	  dCT	  values	  from	  all	  four	  
condition:	  uninfected	  wild	   type,	   infected	  wild	   type,	  uninfected	  PC-­‐SHHKO	  and	   infected	  PC-­‐
SHHKO.	  Bonferroni	  test	  was	  performed	  as	  post	  ANOVA	  test	  to	  assess	  the	  effect	  of	  H.	  pylori	  
on	   target	   genes	   in	  each	  genotype.	  dCT	   values	   from	  uninfected	  mice	  were	   compared	  with	  
dCT	  values	  from	  H.	  pylori	  infected	  mice	  in	  both	  WT	  and	  PC-­‐SHHKO	  conditions.	  For	  graphical	  
presentation	   of	   qPCR	   results,	   for	   each	   gene	   in	   WT	   and	   PC-­‐SHHKO	   conditions,	   ddCT	   was	  
calculated	   by	   subtracting	   dCT	   value	   of	   H.	   pylori	   infected	   group	   from	   dCT	   of	   uninfected	  
group.	  The	  data	  were	  plotted	  as	  2-­‐ddCT	  (mean	  fold	  change).	  A	  P-­‐value	  <0.05	  was	  considered	  
statistically	  significant.	  Interaction	  test	  was	  also	  performed	  to	  study	  the	  interaction	  between	  
infection	  status	  and	  genotype.	  Since	  CT	  value	  is	  inversely	  proportional	  to	  gene’s	  expression	  
level,	  negative	  dCT	  values	  were	  used	  for	  interaction	  test.	  The	  interaction	  plot	  displays	  levels	  
of	   treatment	   (absence	  and	  presence	  of	  H.	  pylori)	  on	   the	  x-­‐axis	  and	  mean	  of	  negative	  dCT	  
values	  for	  each	  treatment	  on	  the	  y-­‐axis.	  A	  separate	  line	  connects	  the	  means	  corresponding	  
to	   each	   level	   of	   the	   trace	   factor	   –	   genotype	   (WT	   and	   PC-­‐SHH-­‐KO).	   	   The	   qPCR	   data	   was	  
analyzed	   using	   R	   statistical	   software.	   Link	   to	   the	  R	   script	   used	   for	   analyzing	   the	   data	   and	  
generating	  graphs:	  http://rpubs.com/marwahsi/20168.	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3.4.4 Mathematical model 
A	  comprehensive	   interaction	  map	  was	  developed	  by	  manual	   curation	  of	  published	  
literature,	   capturing	   key	   signaling	   pathways	   activated	   in	   gastric	   epithelium	   and	   in	  
macrophages	  by	  H.	  pylori	  virulence	  factors.	  For	  our	  mathematical	  model,	  a	  selected	  subset	  
of	   biomolecules	   from	   the	   interaction	  map	  was	   included.	   The	  molecules	  were	   selected	   for	  
inclusion	  if:	  a)	  they	  were	  reported	  in	  the	  literature	  to	  be	  regulated	  with	  H.	  pylori	  SS1	  strain	  
[147,148]	  (as	  SS1	  strain	  was	  used	  in	  our	  experiments)	  and	  b)	  their	  experimental	  trends	  were	  
available	   in	   our	   data.	  Mathematical	   modeling	   of	   very	   large	   networks	   can	   be	   impractical,	  
primarily	  due	   to	  unavailability	  of	  parameter	   values,	  especially	   in	   case	  of	  higher	  organisms	  
[116,151–153].	   	   In	  order	   to	  overcome	   these	  challenges,	   the	  complex	   interaction	  map	  was	  
pruned	  to	  a	  simpler	  reduced	  network	  Figure	  3-­‐2	  focusing	  on	  cytokines	  and	  SHH,	  for	  which	  
experimental	   trends	   were	   available	   [154].	   The	   reduced	   model	   can	   capture	   key	  
characteristics	  of	  the	  larger	  network	  and	  conserve	  the	  regulatory	  mechanisms	  present	  in	  the	  
system	  [151–153].	  Our	  reduced	  model	  compresses	  the	  details	  of	  a	  complex	  pathway	  into	  a	  
“black	   box”,	   which	   can	   be	   scaled	   up,	   by	   adding	   detailed	   components	   as	   needed.	   The	  
reduced	   model	   was	   further	   enriched	   with	   a	   new	   “influence”	   link	   between	   SHH	   and	  
cytokines	  as	  predicted	  by	  our	  experimental	  data.	  It	  must	  be	  noted	  that	  this	  link	  may	  not	  be	  a	  
direct	   interaction	   between	   SHH	   and	   cytokines	   and	   rather	   may	   involve	   an	   indirect	  
mechanism.	  This	  unknown	  mechanism	  is	  currently	  shown	  by	  an	  intermediate	  species	  “X”	  in	  
the	  model	  which	  links	  SHH	  to	  all	  the	  cytokines.	  Equations	  based	  on	  Michaelis-­‐Menten	  and	  
mass	  action	  kinetics	  were	  used	  in	  the	  reduced	  model	  in	  order	  to	  construct	  a	  dynamic	  system	  
that	  describes	  the	  evolution	  of	  the	  biomolecules	  over	  time.	  The	  sampling	  frequency	  (control	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equaling	   time	   zero,	   day	   7	   equaling	   early,	   and	   day	   180	   equaling	   late)	   was	   unlikely	   to	   be	  
sufficient	   for	   obtaining	   detailed	   dynamics	   of	   concentration	   and	   oscillation	   frequencies.	  
Therefore,	  unit-­‐free	  measures	  were	  used	  to	  express	  “time”	  and	  “amount”	  in	  order	  to	  focus	  
on	   the	   qualitative	   behavior	   of	   the	   cytokine	   dynamics.	   The	   kinetic	   parameters	   initially	  
selected	   for	   the	   model,	   represent	   a	   range	   of	   biologically	   feasible	   values	   [155–157].	  
Subsequent	   computational	   optimization	   (iterative	   trial	   and	   error)	   was	   used	   to	   select	   the	  
parameter	  set	   that	  best	  satisfies	   the	   trends	  observed	   in	  experimental	  data	  and	  are	  within	  
biologically	  relevant	  limits.	  This	  approach	  is	  similar	  to	  the	  methodology	  used	  for	  parameter	  
estimation	   for	   computational	   models	   when	   no	   experimental	   values	   are	   available	  
[84,156,158].	  In	  addition	  to	  the	  reactions	  activated	  through	  H.	  pylori	  signaling,	  each	  model	  
species	  is	  activated	  by	  a	  small	  “constitutive”	  flux	  which	  accounts	  for	  some	  basal	  levels	  of	  the	  
species	   formed	   through	   a	   pathway	   either	   not	   represented	   in	   the	   model	   or	   currently	  
unknown.	   Each	   model	   species	   is	   connected	   to	   a	   source	   and	   sink.	   The	   source	   represents	  
inactive	  form	  of	  the	  protein.	  The	  sink	  accounts	  for	  downstream	  signaling	  and	  half-­‐life	  of	  the	  
protein.	  Complete	  list	  of	  model	  assumptions	  are	  provided	  in	  Table	  3-­‐2.	  Ordinary	  Differential	  
Equations	   (ODE)	   were	   simulated	   to	   characterize	   the	   system	   using	   modeling	   tool	  
CellDesigner	   [159].	   Knock-­‐out	   (KO)	   of	   different	   genes	   was	   modeled	   by	   setting	   the	  
concentration	   of	   its	   source	   to	   zero.	   See	   Table	   3-­‐3,	   Table	   3-­‐4	   and	   Table	   3-­‐5	   for	   model	  
















Figure 3-2. Graphical representation of mathematical model of cytokine-SHH network, during H. pylori 
infection.  
This reduced network derived from interaction map, represents the key cytokines activated as host’s immune 
response to H. pylori. Blue arrows represent activation whereas while red arrows depict inhibition. Model 
species with suffix “i” represent the inactive form. The link between SHH and cytokines, as predicted by our 
experimental data is modeled through unknown model species “X” (grey colored). 
3.4.5 Sensitivity Analysis 
To	   ensure	   that	   the	   cyclic	   nature	   of	   our	   mathematical	   model	   is	   not	   depended	   on	  
specific	   parameter	   and	   concentration	   values,	   but	   rather	   observed	   for	   a	   wide	   range	   of	  
biologically	   feasible	   values,	   we	   performed	   sensitivity	   analysis.	   Jacobian	   matrix	   and	  
eigenvalues	   for	   the	   model	   were	   calculated	   using	   simulation	   tool	   –	   Copasi	   [160].	   The	  
parameters	   and	   concentrations	   that	   had	   influence	   on	   the	   imaginary	   part	   of	   eigenvalues	  
were	  selected	  and	  varied	  over	  a	  wide	  range	  of	  values.	  These	  parameter	  values	  were	  varied	  
(+-­‐	   50%	   or	   more)	   to	   assess	   the	   boundary	   value	   for	   the	   parameter	   beyond	   which	   the	  
imaginary	  part	  of	  eigenvalues	  will	  be	  zero	  and	  the	  system	  moves	  towards	  stable	  point.	  
3.4.6 GEO Data 
A	  time-­‐series	  microarray	  dataset	  –	  GSE37938,	  available	  through	  GEO	  (Gene	  Expression	  
Omnibus)	   database	   was	   used	   as	   an	   auxiliary	   data	   set	   in	   order	   to	   analyze	   the	   temporal	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behavior	  of	  the	  genes	  present	  in	  our	  model.	  The	  microarray	  data	  set	  contains	  six-­‐week-­‐old	  
female	  BALB/c	  mice.	  The	  mice	  were	  uninfected	  or	   infected	  with	  SS1	  strain	  of	  H.	  pylori	   for	  
2,7,14	  &	  28	  days.	  A	  total	  of	  71	  samples	  (35	  infected	  +	  36	  uninfected)	  were	  collected	  from	  3	  
cell	   types:	   chief	   cell,	   parietal	   cell	   and	   mucous	   producing	   pit	   cell	   [161].	   This	   dataset	   was	  
selected	  because	  it	  used	  SS1	  strain	  of	  H.	  pylori,	  which	  was	  also	  used	  as	  in	  our	  experimental	  
data	   and	   this	   dataset	   contained	   data	   for	   parietal	   cells.	  We	   extracted	   and	   analyzed	   time-­‐
series	  data	  for	  IL-­‐10,	  IFNγ,	  IL-­‐1β	  from	  GSE37938	  dataset.	  Data	  was	  not	  available	  for	  SHH	  and	  
MIP-­‐2	  while	  IL-­‐12	  data	  was	  not	  used	  for	  analysis	  due	  to	  large	  number	  of	  missing	  values.	  For	  
a	  given	  probe,	  median	  of	   its	  expression	  values	  was	  calculated	   for	  each	  time	  point.	  Probes	  
with	   two	   or	  more	  missing	   values	   for	  more	   than	   one	   time	   point,	  were	   not	   considered	   for	  
further	  analysis.	  The	  median	  values	  of	  a	  probe	  from	  both	  uninfected	  and	  H.	  pylori	  infected	  
mice	  were	  plotted	  against	  time	  to	  study	  their	   trajectory	   in	  the	  two	  conditions.	  To	  address	  
the	   problem	   of	   probe	   selection	   in	   case	   of	   multiple	   probes	   representing	   the	   same	   gene,	  
median	   value	  was	   taken	   for	  probes	  with	   same	  Genbank	   ID	   (GB_list	   ID)	  while	  probes	  with	  
different	  Genbank	  ID	  were	  analyzed	  separately.	  Plots	  are	  shown	  only	  for	  Genbank	  IDs	  that	  
are	   represented	   by	   at	   least	   three	   probes.	   Link	   to	   the	   R	   script	   used	   for	   extracting	   and	  
analyzing	  the	  data:	  http://rpubs.com/marwahsi/8932	  
3.5 Results 
3.5.1 SHH positively regulates cytokine expression during H. pylori infection 
Interaction	  plots	  shown	  in	  Figure	  3-­‐3	  examines	  if	  H.	  pylori	  affects	  cytokine	  expression	  and	  
if	   this	  effect	   is	  different	   in	  WT	  and	  PC-­‐SHHKO	  mice.	  Non-­‐parallel	   lines	   that	  do	  not	  cross	  or	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crossing	  lines,	  imply	  an	  interaction	  effect	  between	  the	  two	  factors	  (genotype	  and	  infection	  
status)	   [162].	   	   An	   interaction	   effect	   between	   genotype	   and	   infection	   was	   observed	   for	  
expression	  of	  all	  cytokines.	  Parallel	   lines	  would	  have	  implied	  that	  the	  effect	  of	  H.	  pylori	  on	  
cytokine	  expression	  is	  the	  same	  in	  WT	  and	  PC-­‐SHHKO	  mice.	  On	  day	  7,	  the	  interaction	  effect	  
was	   statistically	   significant	   for	   IL-­‐12	   and	   IL-­‐10	   but	   not	   for	   IL-­‐1β	   and	  MIP-­‐2.	   For	   day	   180,	  
statistically	  significant	  interaction	  effect	  between	  genotype	  and	  infection	  was	  observed	  for	  
all	  cytokines.	  	  	  
Two-­‐way	  ANOVA	  test	  was	  performed,	  comparing	  dCT	  values	  from	  all	  four	  conditions	  
(WT+	   Brucella	   Broth,	   WT	   +	   H.	   pylori,	   PC-­‐SHHKO	   +	   Brucella	   Broth,	   PC-­‐SHHKO	   +	   H.	   pylori),	  
followed	  by	  Bonferroni	  test	  to	  compare	  specific	  groups	  (Figure	  3-­‐4).	  All	  cytokines	  showed	  a	  
statistically	  significant	  increase	  with	  H.	  pylori	  in	  WT	  mice,	  on	  both	  day	  7	  and	  day	  180	  (except	  
MIP-­‐2	  on	  day	  7,	  which	  increased	  with	  a	  P-­‐value	  of	  0.05).	  However,	  this	  increase	  in	  cytokines’	  
expression	  with	  H.	  pylori	  was	  not	  observed	   in	  PC-­‐SHHKO	  mice.	  These	  observations	   suggest	  
the	  potential	  role	  of	  SHH	  in	  positive	  regulation	  of	  expression	  of	  IL-­‐12,	  IL-­‐1β,	  IL-­‐10,	  IFNγ	  and	  
MIP-­‐2	  during	  H.	  pylori	  infection.	  An	  unexpected	  trend	  was	  observed	  for	  IL-­‐10	  on	  day	  180	  in	  
PC-­‐SHHKO	   mice	   -­‐	   IL-­‐10	   expression	   was	   significantly	   lower	   in	   H.	   pylori	   infected	   mice	   as	  
compared	  with	  uninfected	  mice	  on	  day	  180,	  although	  it	  did	  not	  change	  significantly	  with	  H.	  
pylori	  on	  day	  7.	  
It	   is	   interesting	   to	   note	   that	   our	   analysis	   of	   experimental	   data	   indicates	   a	   positive	  
regulation	  of	  the	  cytokines’	  expression	  involving	  SHH.	  However,	  current	  pathway	  databases	  
(for	   example	   Strings,	   Pathway	   Commons),	   and	   molecular	   circuits	   (wiring	   diagram	   of	  
interactions	   among	   genes	   and	   proteins)	   derived	   through	   manual	   curation	   of	   current	  
literature,	  fail	  to	  identify	  the	  positive	  regulation.	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Figure 3-3. Interaction between infection status and genotype.  
RNA was extracted from stomachs of uninfected (-HP) and H. pylori-infected (+HP) wild type (WT) and 
parietal cell specific SHH knock out (PC-SHH-KO) mice 7 and 180 days post-inoculation. Expression of genes 
was measured by qPCR and interaction test was performed. Parallel lines would imply that H. pylori has same 
effect on gene’s expression in WT and PC-SHHKO mice whereas intersecting or non-parallel lines would 
indicate an interaction between genotype and infection. The graphs show interaction plot between infection 
status and genotype for (A) IL1β on day 7, (B) IL1β on day 180, (C) IL-12 on day 7, (D) IL-12 on day 180, (E) 
MIP-2 on day 7 (F) MIP-2 on day 180 (G) IL-10 on day 7 and (H) IL-10 on day 180. P-value for interaction 
between infection and genotype were calculated by two-way ANOVA test. Y-axis: mean of negative dCT value 
of cytokine, X-axis: infection status, trace-factor: genotype. 
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Figure 3-4. Effect of H. pylori on SHH and cytokines's expression in WT and PC-SHHKO mouse 
stomachs, day 7 and day 180 post-inoculation.  
RNA was extracted from stomachs of uninfected and H. pylori-infected wild type (WT) and parietal cell-
specific SHH knock out (PC-SHH-KO) mice 7 and 180 days post-inoculation. Expression of genes was 
measured by qPCR and two-way ANOVA test was performed, followed by Bonferroni test to compare 
uninfected (-HP) with H. pylori infected group (+HP) in each genotype. The graphs show average fold change 
in expression of IL-1β (A, B), IL-12 (C, D), MIP-2 (E, F), IL-10 (G, H) and SHH (I, J) upon H. pylori infection 




3.5.2 Mathematical Model Behavior  
An	  important	  goal	  of	  model	  building	  is	  to	  ensure	  that	  the	  model	  can	  recapitulate	  the	  
experimental	  trends.	  SHH	  knock-­‐out	  condition	  was	  tested	  in	  the	  model	  that	  is	  curated	  using	  
current	  pathway	  databases	  and	  literature.	  This	  model	  lacks	  the	  putative	  positive	  regulation	  
link	  (kcat9=0)	  suggested	  by	  our	  qPCR	  analysis.	  The	  model	  exhibited	  no	  change	  in	  levels	  of	  IL-­‐
12,	   IL-­‐10,	   IL-­‐1β,	   IFNγ	   or	  MIP-­‐2	   upon	   simulating	   SHH	   KO	   condition.	   In	   our	  model	  with	   the	  
putative	  link,	  all	  cytokines:	  IL-­‐12,	  IL-­‐1β,	  IFNγ,	  IL-­‐10	  and	  MIP-­‐2	  decreased	  with	  SHH	  knock-­‐out	  
(Figure	  3-­‐5),	   aligning	   the	  model	   closer	   to	   the	  experimental	   results.	   The	  decrease	   in	  MIP-­‐2	  





Figure 3-5. In-silico SHH KO results show a decrease in cytokines as compared to WT.  
SHH KO condition was simulated by setting SHHi to zero. Graph A-F shows profiles of (A) SHH (B) IL-1β (C) 
IL12 (D) IFNγ (E) MIP2 (F) IL10. Wild type condition (SHHi=1) is shown in green and in-silico SHH KO 





Next,	  we	  assessed	  the	  effect	  of	  H.	  pylori	  on	  the	  temporal	  profile	  for	  all	  model	  species	  
in-­‐silico.	  The	  simulation	  results	  align	  qualitatively	  with	  the	  experimental	  trends	  of	  cytokines.	  
All	  cytokines	  increased	  with	  switching	  H.	  pylori	  “on”	  in	  the	  model.	  Temporal	  profile	  for	  key	  
model	  species	  is	  compared	  in	  the	  presence	  and	  absence	  of	  H.	  pylori	  in	  Figure	  3-­‐6.	  Dynamic	  
modeling	  of	  the	  reduced	  network	  shows	  that	  with	  H.	  pylori	  stimulation,	  there	  is	  increase	  in	  
NFĸB	   which	   transcribes	   MIP-­‐2	   and	   SHH.	   SHH	   activates	   IL-­‐1β,	   IL-­‐12	   and	   IL-­‐10	   through	  
unknown	  mechanism	  (shown	  through	  “X”	  in	  the	  model).	  IL-­‐10	  in	  turn	  inhibits	  NFĸB,	  forming	  
a	  negative	  feedback	  loop.	  This	  inhibition	  decreases	  NFĸB,	  which	  lowers	  SHH	  and	  eventually	  
decreases	  IL-­‐10	  and	  other	  cytokines.	  The	  decrease	  in	  IL-­‐10	  relieves	  the	  inhibition	  on	  NFĸB,	  
allowing	   it	   to	  rise	  again.	  These	   interactions	  between	  NFĸB,	  SHH	  and	   IL-­‐10	  form	  a	  negative	  
feedback	  loop	  and	  give	  rise	  to	  damped	  oscillations	  in	  the	  model	  (Figure	  3-­‐6	  B).	  	  
To	  understand	  the	  role	  of	  the	  anti-­‐inflammatory	  cytokine	  IL-­‐10	  in	  our	  model	  circuit,	  
we	  simulated	  overexpression	  and	  knock-­‐out	  IL-­‐10	  conditions	  in	  the	  model.	  Overexpression	  
of	  IL-­‐10	  led	  to	  decrease	  in	  NFĸB	  and	  in	  all	  the	  cytokines	  examined	  while	  knock-­‐out	  of	  IL-­‐10	  in	  
the	   model	   relieved	   the	   inhibition	   on	   NFĸB	   and	   resulted	   in	   increase	   in	   NFĸB	   and	   in	   pro-­‐
inflammatory	   cytokines	   downstream	   (Figure	   3-­‐7).	   Our	   in-­‐silico	   outcomes	   qualitatively	  
matched	  published	  results	  of	  similar	  experiments.	  Robinson	  et	  al	  studied	  the	  effect	  of	  IL-­‐10	  
in	   gastric	   epithelial	   cells	   (AGS	   cell	   line)	   [144]	   where	   they	   showed	   that	   addition	   of	  
recombinant	   human	   IL-­‐10	   to	   co-­‐cultures	   of	  H.	   pylori	   strain	   60190	   with	   AGS	   cells	   caused	  
decrease	   in	   nuclear	   NFĸB	   and	   IL-­‐8.	   Similar	   decreasing	   trends	   in	   NFĸB	   and	  MIP-­‐2	   (murine	  
homologue	  of	  human	  IL-­‐8)	  were	  observed	  with	  increase	  of	  IL-­‐10	  in	  our	  model	  (Figure	  3-­‐7	  A,	  
B).	  Knock-­‐out	  of	  IL-­‐10	  in	  our	  model	  relieved	  the	  inhibition	  on	  NFĸB	  and	  resulted	  in	  increase	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in	  NFĸB	  and	  in	  pro-­‐inflammatory	  cytokines	  downstream.	  Figure	  3-­‐7	  C	  shows	  increase	  in	  pro-­‐
inflammatory	  cytokine	   IFNγ	  with	   IL-­‐10	  KO	  as	  compared	  to	  that	   in	  WT,	  thus	  suggesting	  the	  
potential	  protective	  role	  of	  IL-­‐10	  against	  H.	  pylori	  mediated	  gastritis.	  Bodger	  et	  al	  have	  also	  
suggested	   that	   IL-­‐10	   secretion	   during	   H.	   pylori	   infection	   may	   serve	   a	   protective	   role,	  
reducing	   local	   tissue	   damage	   caused	  by	   inflammation	   [163].	   Ismail	   et	   al	   have	   shown	   that	  
Helicobacter	   felis	   infection	   in	   IL-­‐10	   knock-­‐out	   in	   mice	   resulted	   in	   a	   higher	   inflammation	  
score	   and	   severe	   gastritis	   as	   compared	   to	   that	   in	   infected	  wild	   type	  mice	   [97].	   They	   also	  
cultured	   splenocytes	   from	   control	   uninfected	   and	  H.	   felis-­‐infected	  WT	   and	   IL-­‐10	   KO	  mice,	  
with	   sonicated	  H.	   felis	  Ag	   and	   the	   culture	   supernatants	   were	   evaluated	   for	   the	  
concentration	  of	   IFN-­‐γ.	  Splenocytes	   from	  H.	   felis-­‐infected	  WT	  mice	  produced	   low	   levels	  of	  





	  	  	  	   	  
Figure 3-6. Temporal profiles of model species in uninfected and infected conditions.  
Simulation results comparing temporal profiles of model species in (A) absence and (B) presence of H. pylori.  
Graph C-F show temporal profiles of (C) SHH (D) MIP-2 (E) IL-1β and (F) IL-10 in absence and presence of 







Figure 3-7. In-silico IL-10 knock-out and overexpression.  
Effect of IL-10 knock-out and overexpression on (A) NFkB (B) MIP-2 and (C) IFNγ (D) IL-1β (E) IL-12 and 
(F) SHH. Wild type condition (IL10i=1) is shown in black, in-silico IL-10 knok-out (IL10i=0) in red and in-










3.5.3 Temporal Analysis of GEO Data 
We	   also	   analyzed	   a	  microarray	   time-­‐series	   dataset,	   available	   through	   the	   GEO	   database.	  
This	  data	  allowed	  us	  to	  perform	  a	  separate	  investigation	  of	  the	  temporal	  profile	  of	  IL-­‐1β,	  IL-­‐
10	   and	   IFNγ	   for	   both	   mock-­‐infected	   and	   H.	   pylori	   infected	   mice	   using	   the	   alternative	  
technology	  of	  microarrays.	   Figure	  3-­‐8	   shows	   the	   trajectory	  of	   the	   three	   cytokines	   in	   chief	  
cells,	  parietal	  cells,	  and	  pit	  cells,	  for	  day	  2,	  7,	  14	  and	  28.	  This	  time-­‐based	  analysis	  of	  the	  data	  
further	  suggests	  that	  these	  cytokines	  show	  a	  cyclic	  behavior	  as	  opposed	  to	  a	  linear	  trend.	  	  
3.5.4 Sensitivity and Stability Analysis 
Steady	   state	  or	  oscillatory	  behavior	  of	   a	   system	   that	   is	   defined	  by	   a	   set	   of	   ordinary	  
differential	   equations	   can	   be	   determined	   by	   eigenvalues	   derived	   from	   Jacobian	  matrix	   of	  
that	   system	   Table	   2-­‐2.	   We	   used	   the	   above	   mathematical	   principles	   to	   investigate	   the	  
behavior	  of	  our	  model.	  The	  damped	  oscillatory	  nature	  of	  our	  model,	  for	  example,	  depends	  
on	  the	  negative	  inhibition	  of	  NFĸB	  by	  IL-­‐10	  and	  it	  is	  deduced	  from	  the	  complex	  eigenvalues	  
(with	   negative	   real	   part)	   of	   the	   system’s	   response.	   Removal	   of	   this	   inhibitory	   link	   in	   the	  
model	  results	  in	  steady	  state	  behavior	  (Figure	  3-­‐9)	  -­‐	  which	  can	  be	  mathematically	  identified	  
with	  the	  vanishing	  imaginary	  part	  of	  the	  eigenvalues.	  A	  sensitivity	  analysis	  is	  also	  performed	  
to	  find	  the	  range	  of	  parameters	  across	  which	  the	  model	  displays	  damped	  oscillations.	  These	  
results	   indicate	   that	   the	   cyclic	   behavior	   of	   the	   model	   remains	   viable	   within	   a	   large,	  
biologically	   feasible,	   parameter	   region	   and	   is	   not	   limited	   to	   specific	   parameters	   and	  
concentration	   values.	   The	   results	   presented	   in	   Table	   3-­‐1	   show	   that	   the	   model	   exhibits	  




3.6 Key Findings 
• SHH positively regulates expression of cytokines like IL-12, IL-1β, MIP-2, IL-10, however 
the mechanism remains unclear. 
• Our model suggests that NFĸB, SHH and the cytokines engage in a feedback loop which 
can result in damped oscillations. 
• We use the mathematical model as a tool to gain insights into cytokine and SHH 
relationship during H. pylori infection and as a hypotheses generating tool to predict host 
responses that may be associated with gastric disease or clinical treatments that may 
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Figure 3-8. Trajectories of cytokines in mock-infected and H. pylori infected mice from GEO microarray 
dataset. A) IL-10, (B) IL-1β and (C) IFNγ for day 2, 7, 14 and 28 from chief, parietal and pit cell of mock-
infected and H. pylori infected mice. The temporal profiles indicate that these cytokines potentially display a 
cyclic expression pattern in response to H. pylori infection. 
	  
	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  
Figure 3-9. Temporal profiles of model species, in absence of negative feedback on NFĸB by IL-10.  
The damped oscillatory nature of the model depends on the negative inhibition of NFĸB by IL-10. Removal of 
this inhibitory link in the model results in steady state behavior. 
 
Table 3-1. Sensitivity Analysis of model parameters for damped oscillations. Key parameters and their 
range for which the model shows damped oscillations. 
Parameter  Name   (re20)  k1   (re23)  k1   (re18)  k1   (re25)  k1   Hpylori  
Parameter  Range   0.005  to  0.5   0.02  to  0.2   0.005  to  0.5   0.01  to  0.2   1  to  100  
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Table 3-2 Model Assumptions 
• Model	   compresses	   the	  details	  of	  a	   complex	  pathway	   into	  a	   “black	  box”,	  which	  can	  be	  
scaled	   to	   larger,	   detailed	   components	   when	   needed.	   For	   example	   activation	   (nuclear	  
transport)	  of	  NFĸB	  involves	  activation	  of	  ERK,	  AKT	  pathways	  by	  H.	  pylori	  virulence	  factors	  
that	  includes	  many	  steps,	  has	  been	  compressed	  to	  a	  single	  step.	  Similarly,	  cellular	  details	  
of	  transcription,	  translation	  and	  post	  translation	  modifications	  are	  not	  shown.	  The	  focus	  
of	  this	  model	   is	  to	  provide	  a	  high	  level	  understanding	  of	  cytokine-­‐SHH	  circuit	  during	  H.	  
pylori	  infection.	  
• Equations	  were	  based	  on	  Michaelis	  Menten	  and	  mass	  action	  kinetics.	  
• “Time”	  and	  “concentration”	  are	  expressed	  in	  arbitrary	  units	  as	  we	  do	  not	  have	  enough	  
experimental	   data	   to	   confidently	   measure	   proteins’	   concentration	   or	   frequency	   of	  
oscillations.	  
• Kinetic	  parameters	   initially	   selected	   for	   the	  model,	   represented	  a	   range	  of	  biologically	  
feasible	   values	   [155–157].	   Subsequent	   computational	   optimization	   (iterative	   trial	   and	  
error)	  was	  used	   to	   select	   the	  parameter	   set	   that	  best	   satisfies	   the	   trends	  observed	   in	  
experimental	  data	  and	  are	  within	  biologically	  relevant	  limits.	  
• The	   interaction	  map	   focuses	  on	  key	   signaling	  pathways	  activated	   in	   gastric	  epithelium	  
and	  in	  macrophages,	  by	  H.	  pylori	  virulence	  factors.	  Pathways	  in	  other	  immune	  cells	  are	  
currently	   not	   included	   but	   in	   future	   it	   will	   be	   of	   great	   value	   to	   include	   them	   in	   both	  
interaction	  map	  and	  model.	  




Table 3-3 Mathematical equations used in the model. 
Reaction	  Id	   Reactants	   Products	   Modifiers	   Equation	  
re1	   NFKBi	   NFKB	  
Hpylori,	  
IL10	  
kcat1	  *	  Hpylori	  *	  NFKBi	  /	  (km1	  *	  (1	  +	  IL10	  
/	  Ki1)	  +	  NFKBi)	  
re2	   NFKBi	   NFKB	  
	  
v1	  *	  NFKBi	  /	  (k1	  +	  NFKBi)	  
re3	   NFKB	   NFKBi	  
	  
v1	  *	  NFKB	  /	  (k1	  +	  NFKB)	  
re4	   MIP2i	   MIP2	  
	  
v1	  *	  MIP2i	  /	  (k1	  +	  MIP2i)	  
re5	   MIP2i	   MIP2	   NFKB	   kcat5	  *	  NFKB	  *	  MIP2i	  /	  (km5	  +	  MIP2i)	  
re6	   MIP2i	   MIP2	   X	   kcat6	  *	  X	  *	  MIP2i	  /	  (km6	  +	  MIP2i)	  
re7	   SHHi	   SHH	   NFKB,	  IL1b	  
kcat7	  *	  NFKB	  *	  SHHi	  /	  (km7	  *	  (1	  +	  IL1b	  /	  
Ki7)	  +	  SHHi)	  
re8	   SHHi	   SHH	  
	  
v1	  *	  SHHi	  /	  (k1	  +	  SHHi)	  
re9	   Xi	   X	   SHH	   kcat9	  *	  SHH	  *	  Xi	  /	  (km9	  +	  Xi)	  
re10	   IL1bi	   IL1b	   X	   kcat10	  *	  X	  *	  IL1bi	  /	  (km10	  +	  IL1bi)	  
re11	   IL1bi	   IL1b	  
	  
v1	  *	  IL1bi	  /	  (k1	  +	  IL1bi)	  
re12	   IL12i	   IL12	   X	   kcat12	  *	  X	  *	  IL12i	  /	  (km8	  +	  IL12i)	  
re13	   IL12i	   IL12	  
	  
v1	  *	  IL12i	  /	  (k1	  +	  IL12i)	  
re14	   IL10i	   IL10	   X	   kcat14	  *	  X	  *	  IL10i	  /	  (km14	  +	  IL10i)	  
re15	   IL10i	   IL10	  
	  
v1	  *	  IL10i	  /	  (k1	  +	  IL10i)	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re16	   IFNgi	   IFNg	  
IL12,	  
Hpylori	  
kcat16	  *	  Hpylori	  *	  IL12	  *	  IFNgi	  /	  (km16	  +	  
IFNgi)	  
re17	   IFNgi	   IFNg	  
	  
v1	  *	  IFNgi	  /	  (k1	  +	  IFNgi)	  
re18	   NFKB	   Sink	  
	  
NFKB	  *	  k1	  
re19	   MIP2	   Sink	  
	  
MIP2	  *	  k1	  
re20	   SHH	   Sink	  
	  
SHH	  *	  k1	  
re21	   IL1b	   Sink	  
	  
IL1b	  *	  k1	  
re22	   IL12	   Sink	  
	  
IL12	  *	  k1	  
re23	   IL10	   Sink	  
	  
IL10	  *	  k1	  
re24	   IFNg	   Sink	  
	  
IFNg	  *	  k1	  
re25	   X	   Sink	  
	  




Table 3-4 Species’ parameters used in the model. 
Species	  Name	   Initial	  Quantity	   Constant	  
Hpylori	   10	   TRUE	  
NFKB	   0.1	   FALSE	  
NFKBi	   1	   TRUE	  
MIP2	   0.1	   FALSE	  
MIP2i	   1	   TRUE	  
IL1b	   0.1	   FALSE	  
SHHi	   1	   TRUE	  
SHH	   0.1	   FALSE	  
IL10	   0.1	   FALSE	  
X	   0	   FALSE	  
IL1bi	   1	   TRUE	  
Xi	   1	   TRUE	  
IL10i	   1	   TRUE	  
IL12i	   1	   TRUE	  
IL12	   0.1	   FALSE	  
IFNgi	   1	   TRUE	  
IFNg	   0.1	   FALSE	  




Table 3-5 Kinetic parameters used in the model. 
Reaction	  Id	   Parameter	  Name	   Value	  
(re1)	   km1	   0.521	  
(re1)	   kcat1	   0.516	  
(re1)	   Ki1	   0.702	  
(re2)	   v1	   0.2	  
(re2)	   k1	   0.5	  
(re3)	   v1	   0.5	  
(re3)	   k1	   1	  
(re4)	   v1	   0.1	  
(re4)	   k1	   2	  
(re5)	   kcat5	   0.1	  
(re5)	   km5	   2	  
(re6)	   kcat6	   0.7	  
(re6)	   km6	   4	  
(re7)	   kcat7	   1.01	  
(re7)	   km7	   16.25	  
(re7)	   Ki7	   3.98	  
(re8)	   v1	   0.01	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(re8)	   k1	   8	  
(re9)	   kcat9	   0.211	  
(re9)	   km9	   1.03	  
(re10)	   km10	   10	  
(re10)	   kcat10	   0.5	  
(re11)	   v1	   0.1	  
(re11)	   k1	   10	  
(re12)	   km8	   8	  
(re12)	   kcat12	   0.2	  
(re13)	   v1	   0.05	  
(re13)	   k1	   8	  
(re14)	   kcat14	   0.253	  
(re14)	   km14	   20.1	  
(re15)	   v1	   0.1	  
(re15)	   k1	   20	  
(re16)	   kcat16	   0.03	  
(re16)	   km16	   15	  
(re17)	   v1	   0.1	  
(re17)	   k1	   10	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(re18)	   k1	   0.1	  
(re19)	   k1	   0.2	  
(re20)	   k1	   0.05	  
(re21)	   k1	   0.05	  
(re22)	   k1	   0.04	  
(re23)	   k1	   0.04	  
(re24)	   k1	   0.015	  
(re25)	   k1	   0.04	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Chapter 4: Meta-analysis of gastric cancer and H. pylori 
mediated gastritis microarray data. 
	  
4.1 Background 
Although	  the	  majority	  of	  H.	  pylori	  infected	  individuals	  remain	  symptom-­‐free,	  infection	  
by	   this	  bacteria	   is	   considered	   to	  be	   the	   the	  most	  primary	   cause	  of	   chronic	   gastritis	   and	  a	  
high	   risk	   factor	   for	   peptic	   ulcer	   and	   gastric	   cancer	   [50,51].	   Meta-­‐analyses	   based	   on	  
epidemiologic	   studies	   suggest	   that	   the	   presence	   of	   H.	   pylori	   increases	   the	   risk	   for	  
development	   of	   gastric	   cancer	   by	   2-­‐fold	   to	   5-­‐fold	   [38,53],	   	   whereas	   more	   sensitive	   and	  
strain-­‐specific	   studies	   suggest	   a	   20-­‐fold	   increased	   risk	   [16,164].	   H.	   pylori-­‐infected	   gastric	  
mucosa	   evolves	   through	   stages	   of	   chronic	   gastritis,	   glandular	   atrophy	   and	   intestinal	  
metaplasia	  which	  is	  a	  main	  cause	  of	  intestinal	  type	  of	  gastric	  adenocarcinoma	  [7].	  Atrophic	  
gastritis,	   accompanied	  with	   loss	   of	   parietal	   cells	   and	  hypochlorhydria,	   is	   highly	   associated	  
with	  development	  of	  gastric	  cancer	  [165].	  However,	  the	  molecular	  details	  that	  link	  H.	  pylori	  
mediated	   atrophic	   gastritis	   and	   gastric	   cancer	   are	   not	   well	   understood.	   Identification	   of	  
genes	  and	  pathways	  which	  are	  dis-­‐regulated	  during	  gastric	   cancer	  and	  H.	  pylori	  mediated	  
atrophic	  gastritis	  will	  enhance	  our	  current	  knowledge	  about	  the	  molecular	  details	  which	  link	  






To	   identify	   the	  molecular	   signature	   that	   is	  common	   to	   gastric	   cancer	   and	  H.	  pylori	  
mediated	  gastric	  atrophy.	  
4.3 Methods 
4.3.1 Datasets:  
Microarray	   data	   comparing	   healthy	   vs.	   disease	   tissue	   was	   obtained	   from	   the	   Gene	  
Expression	   Omnibus	   (GEO)	   [166]	   database	   Table	   4-­‐1.	   Gse27411	   [165]	   contains	   data	   from	  
patients	   who	   were	   admitted	   for	   endoscopy	   due	   to	   dyspepsia,	   malabsorption	   or	   anemia.	  
Patients	  not	  suffering	  from	  extragastric	  malignancy	  or	   inflammatory	  disease	  were	  selected	  
and	  classified	  into	  two	  groups:	  
i. without	  current	  H.	  pylori	  infection	  (HP-­‐	  ,n=6).	  
ii. with	  current	  or	  past	  H.	  pylori-­‐infection	  and	  corpus-­‐predominant	  atrophic	  gastritis	   (Atr,	  
n=6).	  
From	   these	   patients,	   biopsies	  from	  the	  antrum	   and	  corpus	  mucosa	   were	   obtained	   during	  
endoscopy.	  GSE27342	  and	  GSE13861	  with	  sample	  size	  of	  160	  and	  84	  respectively	  represent	  







Table 4-1. Sample size of GEO datasets used in the study. GSE27411 represents the H. pylori mediated 
atrophic gastritis dataset while GSE27342 and GSE13861 are the gastric cancer datasets. 
GEO	  ID	  
Sample	  size	  (Stomach	  tissue)	  
Treatment	   Control	  
GSE27411	   6	  HP-­‐	   6	  Atr	  
GSE27342	   80	  Tumor	   80	  Adjacent	  Normal	  
GSE13861	   65	  Tumor	   19	  Adjacent	  Normal	  
	  
	  
4.3.2 Differential Gene Expression Analysis 
Differential	   expression	   analysis	   for	   each	   dataset	   was	   performed	   in	   R	   version	   3.12	  
(programming	   language	   and	   environment	   for	   statistical	   computing)	   using	   Limma	   package	  
[167]	  from	  Bioconductor.	  Limma	  ﬁts	  a	  linear	  model	  to	  the	  expression	  data	  for	  each	  gene.	  It	  
uses	   emperical	   Bayes	  method	   to	  moderate	   the	   standard	   errors	   of	   the	   estimated	   log	   fold	  
changes.	   Benjamini-­‐Hochberg	   test	  was	   used	   for	  multiple	   correction	   and	   genes	  with	   False	  
Discovery	  Rate	  (FDR)	  <	  0.05	  were	  considered	  to	  be	  differentially	  expressed.	  For	  Gse27411,	  
corpus	   and	   antrum	   samples	  were	   analyzed	   separately	   as	   they	   represent	   different	   tissues;	  
different	   genes	   are	   preferentially	   expressed	   in	   antrum	   and	   corpus	   tissue	   [165].	   Since	  
Gse27342	   represents	   paired	   data,	   paired	   limma	   test	  was	   used	   for	   its	   analysis.	   Functional	  
enrichment	   of	   Differentially	   Expressed	   Genes	   (DEG),	   common	   among	   the	   3	   datasets	   was	  
performed	  by	  submitting	  entrez	  ids	  of	  DEG	  to	  the	  ToppFun	  tool	  [168].	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4.3.3 Connectivity Map Analysis 
Entrez	   gene	   identifiers	   of	   Differentially	   Expressed	  Genes	   (DEG)	   from	   the	  microarray	  
datasets	  were	  mapped	  to	  Affymetrix	  HG-­‐U133A	  probesets	  using	  hgu133a.db	  package	  	  [169]	  	  
in	  R.	  The	  DEG	  common	  across	  the	  three	  datasets	  were	  used	  as	  input	  query	  for	  Connectivity	  
Map	   (CMap)	   version	   2	   [170]	   	   analysis.	   Compounds	   with	   negative	   enrichment	   scores	   and	  
permutation	  P-­‐value	  <	  0.05	  were	  selected	  as	  a	  basis	  for	  to	  identifying	  compounds	  which	  can	  
maximally	  reverse	  the	  gene	  signature.	  	  
	  
4.4 Results 
The	  number	  of	  Differentially	  Expressed	  Genes	  (DEG)	  in	  each	  dataset	  is	  summarized	  in	  
Table	   4-­‐2.	   To	   identify	   genes	   that	   are	   differentially	   expressed	   during	   H.	   pylori	   mediated	  
atrophic	   gastritis,	   Atrophy	   group	   (Atr)	   was	   compared	   to	   uninfected	   (HP-­‐)	   group	   from	  
GSE27411.	  In	  the	  corpus	  tissue,	  684	  genes	  were	  observed	  to	  be	  up-­‐regulated	  and	  665	  genes	  
to	   be	   down-­‐regulated	   during	   H.	   pylori	   mediated	   atrophic	   gastritis	   as	   compared	   to	  
uninfected	  corpus.	  However,	  there	  were	  no	  DEG	  observed	  in	  the	  antrum	  samples	  (between	  
HP-­‐	  and	  Atr	  (Atrophy	  patients))	  because	  for	  most	  of	  the	  patients	  in	  this	  dataset,	  atrophy	  was	  
predominantly	   in	  the	  corpus	  tissue	  and	  usually	  absent	  or	  mild	   in	  the	  antrum	  region.	  Venn	  
diagrams	  of	  DEG	  common	  among	  the	  gastric	  cancer	  and	  H.	  pylori	  mediated	  atrophic	  gastric	  
are	  shown	  in	  Figure	  4-­‐1.	  	  There	  were	  57	  up-­‐regulated	  genes	  and	  86	  down-­‐regulated	  genes	  
that	  were	  differentially	  expressed	   in	  all	   the	   three	  datasets.	   Functional	   Enrichment	  of	  DEG	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common	  among	  the	  three	  datasets	  was	  performed	  using	  ToppFun	  tool.	  Topmost	  biological	  
processes	  and	  pathways	  enriched	  for	  the	  common	  DEG	  are	  shown	  in	  Table	  4-­‐3.	  	  
 
Table 4-2. Number of Differentially Expressed Genes (DEG) in gastric cancer and H. pylori mediated 
atrophic gastritis datasets. n = sample size. 
GEO	  ID	   Number	  of	  Differentially	  Expressed	  Genes	  (DEG)	  
	   Up-­‐regulated	   Down-­‐regulated	  
Gse273411	  –	  Corpus	  (n=6)	   684	   665	  
Gse273411	  –	  Antrum	  (n=6)	   0	   0	  
Gse27342	  (n=160)	   652	   341	  














Figure 4-1. Venn diagram showing intersection between Differentially Expressed Genes (DEG) from 
gastric cancer and H. pylori mediated atrophic gastritis. 
	  
4.5 Discussion 
Genes	   like	   claudins	   that	   were	   up-­‐regulated	   in	   both	   gastric	   cancer	   and	   H.	   pylori	  
mediated	  atrophic	  gastritis	  are	   involved	   in	  pathways	  related	  to	  cell-­‐cell	  adhesion,	   	  cell-­‐cell	  
communication,	   tight	   junctions	  and	   leukocyte	   transendothelial	  migration.	  An	   independent	  
microarray	   study	   (not	   used	   in	   our	   meta-­‐analysis)	   has	   compared	   gastric	   adenocarcinoma	  
with	   adjacent	   normal	   tissues	   from	   20	   patients	   and	   it	   has	   demonstrated	   that	   claudin-­‐1	  
(CLDN1)	  is	  one	  of	  the	  most	  consistently	  up-­‐regulated	  genes	  in	  the	  tumors.	  The	  same	  group	  
has	  reported	  CLDN1	  as	  marker	  for	  poor	  post-­‐operative	  prognosis	  and	  has	  suggested	  that	  up-­‐
Up-­‐regulated	  Genes	   Down-­‐regulated	  Genes	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regulated	   genes	   were	   mapped	   to	   cell-­‐adhesion	   and	   collagen-­‐related	   processes	   [171].	   In	  
another	   study,	  Tsai	  et	  al	  analyzed	  microarray	  data	   from	  a	   randomized,	  placebo-­‐controlled	  
trial	  of	  H.	  pylori	  therapy.	  In	  their	  study,	  54	  gastric	  biopsies	  were	  obtained	  from	  27	  subjects	  
(13	   from	   the	   treatment	   and	   14	   from	   the	   placebo	   group)	   with	   chronic	   gastritis,	   atrophy,	  
and/or	   intestinal	   metaplasia.	   Each	   subject	   contributed	   one	   biopsy	   before	   and	   another	  
biopsy	  1	  year	  after	   the	   intervention.	  S100A10,	  a	  gene	   involved	   in	   cell	   cycle	  differentiation	  
and	   protein	   hetero-­‐tetramerization,	  was	   reported	   to	   increase	   over	   time	   in	   placebo	   group	  
and	  decrease	  in	  treatment	  group	  [172].	  An	  independent	  investigation	  by	  another	  group	  has	  
shown	   that	   S100A10	   is	   overexpressed	   in	   gastric	   cancer	   [173].	   EPCAM	   (epithelial	   cell	  
adhesion	  molecule),	  CDH17	   (cadherin	  17)	  and	  ANXA2	   (annexinA2)	  are	  among	  other	  genes	  
that	  were	  predicted	  by	  our	  analysis	  to	  be	  overexpressed	  in	  both	  gastric	  cancer	  and	  H.	  pylori	  
mediated	  gastric	  atrophy.	  EPCAM	  [174],	  CDH17	  [175,176]	  and	  ANXA2	  [177]	  have	  also	  been	  
reported	  to	  be	  up-­‐regulated	  in	  gastric	  cancer.	  	  
Our	   analysis	   shows	   that	   genes	   involved	   in	   gastric	   acid	   secretion,	   potassium	   ion	  
transport	   and	   creatine	   pathways	  were	   down-­‐regulated	   in	   both	   gastric	   cancer	   and	   corpus	  
predominant	   gastric	   atrophy	   associated	   with	   H.	   pylori	   infection.	   It	   has	   been	   previously	  
reported	   that	   in	   subjects	   with	   predominant	   body	   (corpus)	   gastritis,	   acid	   secretion	   is	  
impaired	   and	   the	   subjects	   have	   an	   increased	   risk	   of	   developing	   gastric	   cancer	   [178,179].	  
Qing	  et	  al	  have	  also	  shown	  that	  creatine	  kinase	  –	  brain	  (CKB)	   is	  under-­‐expressed	  in	  gastric	  
cancer	   cells.	   CKB	   is	   expressed	   in	   parietal	   cells	   and	   couples	   functionally	   to	   H-­‐K-­‐ATPase	   to	  
effectively	   provide	   ATP	   for	   proton	   pumping	   [180].	   Complete	   list	   of	   genes,	   which	   were	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differentially	   expressed	   in	   both	   gastric	   cancer	   and	  H.	   pylori	  mediated	   gastric	   atrophy	   are	  
summarized	  in	  Table	  4-­‐6	  and	  Table	  4-­‐7.	  
Table 4-3. Enriched GO processes and pathways in DEG common to gastric cancer and H. pylori 
mediated gastritis datasets. 
Pathways	   Hit	  in	  Up-­‐regulated	  Gene	  List	   q-­‐value	  (Bonferroni)	  

























CLDN4,CLDN3,CLDN7,CLDN2,CLDN1	   3.02E-­‐02	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Biological	  Process	   Hit	  in	  Down-­‐regulated	  Gene	  List	   q-­‐value	  (Bonferroni)	  









































To	   identify	   potential	   compounds	   that	   can	   maximally	   reverse	   the	   common	   gene	  
signature	   identified	   above,	   Broad	   Institute’s	   Connectivity	   Map	   (CMap)	   was	   used.	  
Connectivity	  Map	  is	  a	  collection	  of	  microarray	  expression	  data	  from	  cancer	  cell	  lines	  treated	  
with	  bioactive	  small	  molecules.	  CMap	  portal	  accepts	  disease	  signature	  (lists	  of	  up-­‐regulated	  
and	  down-­‐regulated	  genes)	  as	  an	  input	  and	  uses	  a	  pattern-­‐matching	  algorithm	  to	  compare	  it	  
against	   reference	   gene	   signature	   of	   each	   compound.	   CMap	   assigns	   a	   positive	   enrichment	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score	  to	  a	  compound	  that	  has	  an	  expression	  signature	  similar	  to	  that	  in	  the	  disease,	  and	  a	  
negative	   score	   to	   a	   perturbagen	   that	   has	   an	   expression	   signature	   opposite	   to	   that	   in	   the	  
disease.	  Probes	  corresponding	  to	  the	  57	  upregulated	  and	  86	  downregulated	  genes	  from	  our	  
study	  were	  used	  as	  input	  query	  for	  CMap.	  The	  top	  ranked	  compounds	  are	  shown	  in	  Table	  4-­‐
4.	  The	  role	  of	  these	  compounds	  in	  gastric	  cancer	  is	  summarized	  in	  Table	  4-­‐5.	  
4.6 Limitations 
Gastric	   cancer	   and	   gastric	   atrophy	   data	   were	   obtained	   from	   different	   patients	   and	  
thus	  the	  identified	  genes	  are	  subject	  to	  heterogeneity	  across	  population.	  	  
4.7 Conclusions 
Using	  genomics	  data,	  we	  have	  tried	  to	  identify	  the	  molecular	  signature	  and	  pathways,	  
which	  are	  common	  between	  gastric	  cancer	  and	  H.	  pylori	  mediated	  atrophic	  gastritis.	  Further	  
analysis	   of	   this	   gene	   signature	   can	   help	   us	   identify	   the	   underlying	  molecular	  mechanism	  







Table 4-4. Top ranked compounds with expression profiles opposite to that of common DEG signature 
identified from gastric cancer and H. pylori mediated atrophic gastritis. 
rank	   cmap	  name	   mean	   n	   enrichment	   p	  
1	   vorinostat	   -­‐0.691	   12	   -­‐0.752	   0	  
2	   trichostatin	  A	   -­‐0.344	   182	   -­‐0.356	   0	  
3	   nalbuphine	   -­‐0.517	   5	   -­‐0.761	   0.00146	  
5	   pargyline	   -­‐0.641	   4	   -­‐0.816	   0.00209	  
6	   alpha-­‐estradiol	   -­‐0.412	   16	   -­‐0.441	   0.00233	  
7	   levamisole	   -­‐0.698	   4	   -­‐0.8	   0.0031	  
8	   xylometazoline	   -­‐0.598	   4	   -­‐0.797	   0.00338	  
11	   cefsulodin	   -­‐0.418	   4	   -­‐0.775	   0.00523	  
12	   piperlongumine	   -­‐0.829	   2	   -­‐0.951	   0.00531	  
13	   DL-­‐thiorphan	   -­‐0.786	   2	   -­‐0.949	   0.00561	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Table 4-6. Genes overexpressed in gastric cancer and Helicobacter pylori mediated gastric atrophy 
datasets.  
	  





7045	   TGFBI	   transforming	  growth	  factor,	  beta-­‐induced,	  68kDa	  
6281	   S100A10	   S100	  calcium	  binding	  protein	  A10	  
220042	   DDIAS	   DNA	  damage-­‐induced	  apoptosis	  suppressor	  
113802	   HENMT1	   HEN1	  methyltransferase	  homolog	  1	  (Arabidopsis)	  
90381	   TICRR	   TOPBP1-­‐interacting	  checkpoint	  and	  replication	  regulator	  
126353	   MISP	   mitotic	  spindle	  positioning	  
346389	   MACC1	   metastasis	  associated	  in	  colon	  cancer	  1	  
2706	   GJB2	   gap	  junction	  protein,	  beta	  2,	  26kDa	  
9235	   IL32	   interleukin	  32	  
1044	   CDX1	   caudal	  type	  homeobox	  1	  
5268	   SERPINB5	   serpin	  peptidase	  inhibitor,	  clade	  B	  (ovalbumin),	  member	  5	  
10903	   MTMR11	   myotubularin	  related	  protein	  11	  
26	   AOC1	   amine	  oxidase,	  copper	  containing	  1	  
55711	   FAR2	   fatty	  acyl	  CoA	  reductase	  2	  
83879	   CDCA7	   cell	  division	  cycle	  associated	  7	  
1830	   DSG3	   desmoglein	  3	  
23590	   PDSS1	   prenyl	  (decaprenyl)	  diphosphate	  synthase,	  subunit	  1	  
2984	   GUCY2C	   guanylate	  cyclase	  2C	  
430	   ASCL2	   achaete-­‐scute	  family	  bHLH	  transcription	  factor	  2	  
302	   ANXA2	   annexin	  A2	  
196410	   METTL7B	   methyltransferase	  like	  7B	  
51645	   PPIL1	   peptidylprolyl	  isomerase	  (cyclophilin)-­‐like	  1	  
3904	   LAIR2	   leukocyte-­‐associated	  immunoglobulin-­‐like	  receptor	  2	  
80704	   SLC19A3	   solute	  carrier	  family	  19	  (thiamine	  transporter),	  member	  3	  
10562	   OLFM4	   olfactomedin	  4	  
1604	   CD55	   CD55	  molecule,	  decay	  accelerating	  factor	  for	  complement	  (Cromer	  blood	  group)	  
55365	   TMEM176A	   transmembrane	  protein	  176A	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5445	   PON2	   paraoxonase	  2	  
79814	   AGMAT	   agmatine	  ureohydrolase	  (agmatinase)	  
80201	   HKDC1	   hexokinase	  domain	  containing	  1	  
4680	   CEACAM6	  
carcinoembryonic	  antigen-­‐related	  cell	  adhesion	  molecule	  6	  (non-­‐specific	  cross	  
reacting	  antigen)	  
79949	   PLEKHS1	   pleckstrin	  homology	  domain	  containing,	  family	  S	  member	  1	  
717	   C2	   complement	  component	  2	  
1871	   E2F3	   E2F	  transcription	  factor	  3	  
286676	   ILDR1	   immunoglobulin-­‐like	  domain	  containing	  receptor	  1	  
1364	   CLDN4	   claudin	  4	  
1365	   CLDN3	   claudin	  3	  
1366	   CLDN7	   claudin	  7	  
91862	   MARVELD3	   MARVEL	  domain	  containing	  3	  
1111	   CHEK1	   checkpoint	  kinase	  1	  
344	   APOC2	   apolipoprotein	  C-­‐II	  
4312	   MMP1	   matrix	  metallopeptidase	  1	  (interstitial	  collagenase)	  
9052	   GPRC5A	   G	  protein-­‐coupled	  receptor,	  class	  C,	  group	  5,	  member	  A	  
4192	   MDK	   midkine	  (neurite	  growth-­‐promoting	  factor	  2)	  
9700	   ESPL1	   extra	  spindle	  pole	  bodies	  homolog	  1	  (S.	  cerevisiae)	  
4072	   EPCAM	   epithelial	  cell	  adhesion	  molecule	  
283375	   SLC39A5	   solute	  carrier	  family	  39	  (zinc	  transporter),	  member	  5	  
3692	   EIF6	   eukaryotic	  translation	  initiation	  factor	  6	  
55789	   DEPDC1B	   DEP	  domain	  containing	  1B	  
9843	   HEPH	   hephaestin	  
9075	   CLDN2	   claudin	  2	  
9076	   CLDN1	   claudin	  1	  
4982	   TNFRSF11B	   tumor	  necrosis	  factor	  receptor	  superfamily,	  member	  11b	  
1015	   CDH17	   cadherin	  17,	  LI	  cadherin	  (liver-­‐intestine)	  
634	   CEACAM1	   carcinoembryonic	  antigen-­‐related	  cell	  adhesion	  molecule	  1	  (biliary	  glycoprotein)	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Table 4-7. Genes under-expressed in gastric cancer and Helicobacter pylori mediated gastric atrophy 
datasets.  
	  





1152	   CKB	   creatine	  kinase,	  brain	  
768	   CA9	   carbonic	  anhydrase	  IX	  
85377	   MICALL1	   MICAL-­‐like	  1	  
2690	   GHR	   growth	  hormone	  receptor	  
10242	   KCNMB2	   potassium	  channel	  subfamily	  M	  regulatory	  beta	  subunit	  2	  
1158	   CKM	   creatine	  kinase,	  muscle	  
2694	   GIF	   gastric	  intrinsic	  factor	  (vitamin	  B	  synthesis)	  
9992	   KCNE2	   potassium	  channel,	  voltage	  gated	  subfamily	  E	  regulatory	  beta	  subunit	  2	  
1160	   CKMT2	   creatine	  kinase,	  mitochondrial	  2	  (sarcomeric)	  
3977	   LIFR	   leukemia	  inhibitory	  factor	  receptor	  alpha	  
285704	   RGMB	   repulsive	  guidance	  molecule	  family	  member	  b	  
5005	   ORM2	   orosomucoid	  2	  
124817	   CNTD1	   cyclin	  N-­‐terminal	  domain	  containing	  1	  
53905	   DUOX1	   dual	  oxidase	  1	  
130576	   LYPD6B	   LY6/PLAUR	  domain	  containing	  6B	  
137872	   ADHFE1	   alcohol	  dehydrogenase,	  iron	  containing,	  1	  
5909	   RAP1GAP	   RAP1	  GTPase	  activating	  protein	  
1558	   CYP2C8	   cytochrome	  P450,	  family	  2,	  subfamily	  C,	  polypeptide	  8	  
284434	   NWD1	   NACHT	  and	  WD	  repeat	  domain	  containing	  1	  
4118	   MAL	   mal,	  T-­‐cell	  differentiation	  protein	  
27159	   CHIA	   chitinase,	  acidic	  
222235	   FBXL13	   F-­‐box	  and	  leucine-­‐rich	  repeat	  protein	  13	  
146456	   TMED6	   transmembrane	  emp24	  protein	  transport	  domain	  containing	  6	  
3354	   HTR1E	   5-­‐hydroxytryptamine	  (serotonin)	  receptor	  1E,	  G	  protein-­‐coupled	  
401052	   LOC401052	   uncharacterized	  LOC401052	  
80157	   CWH43	   cell	  wall	  biogenesis	  43	  C-­‐terminal	  homolog	  (S.	  cerevisiae)	  
3485	   IGFBP2	   insulin-­‐like	  growth	  factor	  binding	  protein	  2,	  36kDa	  
2852	   GPER1	   G	  protein-­‐coupled	  estrogen	  receptor	  1	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115111	   SLC26A7	   solute	  carrier	  family	  26	  (anion	  exchanger),	  member	  7	  
5799	   PTPRN2	   protein	  tyrosine	  phosphatase,	  receptor	  type,	  N	  polypeptide	  2	  
221476	   PI16	   peptidase	  inhibitor	  16	  
145957	   NRG4	   neuregulin	  4	  
79917	   MAGIX	   MAGI	  family	  member,	  X-­‐linked	  
3249	   HPN	   hepsin	  
10930	   APOBEC2	   apolipoprotein	  B	  mRNA	  editing	  enzyme,	  catalytic	  polypeptide-­‐like	  2	  
348093	   RBPMS2	   RNA	  binding	  protein	  with	  multiple	  splicing	  2	  
2104	   ESRRG	   estrogen-­‐related	  receptor	  gamma	  
204474	   PDILT	   protein	  disulfide	  isomerase-­‐like,	  testis	  expressed	  
3899	   AFF3	   AF4/FMR2	  family,	  member	  3	  
3772	   KCNJ15	   potassium	  channel,	  inwardly	  rectifying	  subfamily	  J,	  member	  15	  
252995	   FNDC5	   fibronectin	  type	  III	  domain	  containing	  5	  
92737	   DNER	   delta/notch-­‐like	  EGF	  repeat	  containing	  
2752	   GLUL	   glutamate-­‐ammonia	  ligase	  
27329	   ANGPTL3	   angiopoietin-­‐like	  3	  
2243	   FGA	   fibrinogen	  alpha	  chain	  
7108	   TM7SF2	   transmembrane	  7	  superfamily	  member	  2	  
25924	   MYRIP	   myosin	  VIIA	  and	  Rab	  interacting	  protein	  
6340	   SCNN1G	   sodium	  channel,	  non	  voltage	  gated	  1	  gamma	  subunit	  
25928	   SOSTDC1	   sclerostin	  domain	  containing	  1	  
3784	   KCNQ1	   potassium	  channel,	  voltage	  gated	  KQT-­‐like	  subfamily	  Q,	  member	  1	  
148808	   MFSD4	   major	  facilitator	  superfamily	  domain	  containing	  4	  
64714	   PDIA2	   protein	  disulfide	  isomerase	  family	  A,	  member	  2	  
4684	   NCAM1	   neural	  cell	  adhesion	  molecule	  1	  
51660	   MPC1	   mitochondrial	  pyruvate	  carrier	  1	  
333	   APLP1	   amyloid	  beta	  (A4)	  precursor-­‐like	  protein	  1	  
1358	   CPA2	   carboxypeptidase	  A2	  (pancreatic)	  
27087	   B3GAT1	   beta-­‐1,3-­‐glucuronyltransferase	  1	  
81617	   CAB39L	   calcium	  binding	  protein	  39-­‐like	  
64850	   ETNPPL	   ethanolamine-­‐phosphate	  phospho-­‐lyase	  
151126	   ZNF385B	   zinc	  finger	  protein	  385B	  
114132	   SIGLEC11	   sialic	  acid	  binding	  Ig-­‐like	  lectin	  11	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222166	   MTURN	   maturin,	  neural	  progenitor	  differentiation	  regulator	  homolog	  (Xenopus)	  
8789	   FBP2	   fructose-­‐1,6-­‐bisphosphatase	  2	  
135892	   TRIM50	   tripartite	  motif	  containing	  50	  
54102	   CLIC6	   chloride	  intracellular	  channel	  6	  
84952	   CGNL1	   cingulin-­‐like	  1	  
375775	   PNPLA7	   patatin-­‐like	  phospholipase	  domain	  containing	  7	  
27098	   CLUL1	   clusterin-­‐like	  1	  (retinal)	  
2651	   GCNT2	   glucosaminyl	  (N-­‐acetyl)	  transferase	  2,	  I-­‐branching	  enzyme	  (I	  blood	  group)	  
168544	   ZNF467	   zinc	  finger	  protein	  467	  
1000	   CDH2	   cadherin	  2,	  type	  1,	  N-­‐cadherin	  (neuronal)	  
361	   AQP4	   aquaporin	  4	  
154091	   SLC2A12	   solute	  carrier	  family	  2	  (facilitated	  glucose	  transporter),	  member	  12	  
6506	   SLC1A2	   solute	  carrier	  family	  1	  (glial	  high	  affinity	  glutamate	  transporter),	  member	  2	  
1131	   CHRM3	   cholinergic	  receptor,	  muscarinic	  3	  
79981	   FRMD1	   FERM	  domain	  containing	  1	  
495	   ATP4A	   ATPase,	  H+/K+	  exchanging,	  alpha	  polypeptide	  
9455	   HOMER2	   homer	  scaffolding	  protein	  2	  
10863	   ADAM28	   ADAM	  metallopeptidase	  domain	  28	  
496	   ATP4B	   ATPase,	  H+/K+	  exchanging,	  beta	  polypeptide	  
5104	   SERPINA5	   serpin	  peptidase	  inhibitor,	  clade	  A	  (alpha-­‐1	  antiproteinase,	  antitrypsin),	  member	  5	  
887	   CCKBR	   cholecystokinin	  B	  receptor	  
79739	   TTLL7	   tubulin	  tyrosine	  ligase-­‐like	  family	  member	  7	  
2940	   GSTA3	   glutathione	  S-­‐transferase	  alpha	  3	  
7036	   TFR2	   transferrin	  receptor	  2	  








Chapter 5: Drug repurposing for gastric cancer using gene 
expression data. 
-­‐	  Teaching	  new	  tricks	  to	  old	  drugs	  
	  
5.1 Background 
Gastric	  cancer	  is	  the	  3rd	  leading	  cause	  of	  cancer-­‐related	  deaths	  worldwide	  [1],	  with	  5-­‐
year	  survival	  rate	  of	  20%	  [2]	  to	  29%	  [3].	  Oncology	  drug	  development	  efforts	  are	  often	  faced	  
with	  high	  failure	  rate,	   limited	  efficacy,	  high	  cost,	  and	  long	  development	  time.	  	  Only	  one	  of	  
every	   5000–10,000	   prospective	   anticancer	   agents	   receives	   FDA	   approval	   and	   only	   5%	   of	  
oncology	   drugs	   entering	   Phase	   I	   clinical	   trials	   are	   ultimately	   approved	   [181].	   	   Drug	  
repurposing	   is	   one	   of	   the	   alternate	   approaches	   to	   reduce	   the	   high	   cost	   and	   failure	   rates	  
associated	  with	  development	  of	  a	  new	  drug	  de	  novo.	  Drug	  repurposing	  is	  the	  process	  of	  re-­‐
using	  an	  approved	  drug	  for	  a	  different	  indication	  or	  rescuing	  a	  lead	  compound	  that	  failed	  in	  
clinical	   trials	   and	   develop	   it	   to	   treat	   a	   different	   condition.	   The	   key	   advantage	   of	   this	  
approach	   relates	   to	   the	   established	   safety	   profile	   of	   the	   drugs;	   the	   pharmacokinetics,	  
pharmacodynamics,	  and	  toxicity	  of	  the	  compounds	  are	  usually	  known	  because	  of	  the	  prior	  
preclinical	  or	  Phase	  I	  studies	  [182].	  	  
	   With	  decreasing	  cost	  of	  microarray	  and	  next	  generation	  sequencing,	  and	  increasing	  
availability	   of	   open	   source	   genomic	   data,	   signature-­‐based	   method	   offers	   a	   promising	  
approach	   for	   computational	   drug	   repurposing.	   In	   this	   study,	  we	   analyze	   genomic	   data	   to	  
identify	  gene	  signature	  for	  gastric	  cancer	  and	  compare	   it	   to	  the	  gene	  signature	  associated	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with	   known	   drugs.	   We	   then	   prioritize	   potential	   therapeutic	   compounds	   for	   the	   disease	  
based	   on	   this	   signature	   comparison.	   We	   used	   microarray	   data	   from	   GEO	   database	   and	  
Broad	   Institute’s	   Connectivity	   Map	   (CMap)	   portal	   to	   link	   known	   drugs	   with	   the	   genes	  
involved	  in	  the	  disease.	  The	  Connectivity	  Map	  method	  is	  based	  on	  the	  Kolmogorov–Smirnov	  
statistic	  [183]	  using	  a	  nonparametric,	  rank-­‐based,	  pattern-­‐matching	  strategy	  called	  the	  Gene	  
Set	   Enrichment	   Analysis	   (GSEA)	   [184].	   In	   CMap	   approach,	   the	   disease	   query	   signature	   is	  
comprised	  of	  a	  nonrank	  ordered	  list	  of	  genes	  correlated	  with	  the	  disease	  state,	  along	  with	  a	  
sign	   indicating	  whether	  the	  gene	   is	  up-­‐	  or	  down-­‐regulated.	  The	  compound	  reference	  gene	  
expression	  profiles	  are	  also	  represented	  in	  a	  nonparametric	  manner,	  but	  instead	  each	  gene	  
is	  rank-­‐ordered	  by	  its	  degree	  of	  differential	  expression	  relative	  to	  untreated	  controls.	  Each	  
gene	  in	  the	  disease	  query	  signature	  is	  then	  compared	  against	  the	  rank-­‐ordered	  list	  of	  each	  
compound	   reference	   signature,	   and	   the	   strength	   of	   its	   positive	   or	   negative	   connectivity	  
yields	  a	  score	  ranging	  from	  +1	  to	  −1	  for	  each	  compound	  signature	  [170,185]	  	  
	  
5.2 Aim 
To	   identify	   FDA	  approved	  drugs	  or	  nondrug	  bioactive	  agents	   that	   can	  be	  potentially	  








Microarray	  data	  comparing	  control	  vs.	  treatment	  tissue	  was	  obtained	  from	  the	  Gene	  
Expression	  Omnibus	  (GEO)	  [166]	  database	  Table	  5-­‐1.	  A	  key	  challenge	  while	  comparing	  gene	  
expression	   between	   tissues	   obtained	   from	   cancer	   patients	   and	   healthy	   individuals	   is	   the	  
difference	  contributed	  by	  genetic	  heterogeneity	  among	  individuals.	  Thus,	  we	  selected	  only	  
those	   datasets	   from	   GEO	   database,	   where	   both	   tumor	   and	   (adjacent)	   non-­‐tumor	   tissues	  
were	  obtained	  from	  the	  same	  patient,	  thus	  reducing	  the	  error	  due	  to	  genetic	  heterogeneity	  
among	   individuals.	   For	   GSE27342,	   gastric	   cancer	   tissues	   and	   their	   adjacent	   noncancerous	  
tissues	  were	  collected	  from	  80	  non-­‐treated	  patients	  in	  China	  [186].	  In	  GSE13861	  dataset,	  65	  
gastric	   adenocarcinoma	   tissues	   with	   19	   normal	   surrounding	   tissue	   samples	   from	   gastric	  
cancer	  patients	  in	  South	  Korea	  were	  used	  [187].	  For	  drug	  resistance	  signature,	  we	  used	  data	  
from	  GSE14210.	   Here	   gastric	   adenocarcinomas	   were	   obtained	   from	   22	   patients	   in	   South	  
Korea	  who	  initally	  responded	  to	  Cisplatin-­‐Flurouracil	   (CF)	  but	   later	  developed	  resistance	  to	  
the	  chemotherapy	  [188].	  
GEO	  ID	  
Sample	  size	  (Stomach	  tissue)	  
Treatment	   Control	  
GSE27342	   80	  Tumor	   80	  Adjacent	  Normal	  
GSE13861	   65	  Tumor	   19	  Adjacent	  Normal	  
GSE14210	   22	  CF	  –	  Resistant	  Tumor	   22	  CF	  -­‐	  Sensitive	  Tumor	  




5.3.2 Differential Gene Expression Analysis 
Differential	  expression	  analysis	  for	  each	  dataset	  was	  performed	  in	  R	  (version	  3.1.2)	  
using	  Limma	  package	  [167]	  from	  Bioconductor.	  Limma	  ﬁts	  a	  linear	  model	  to	  the	  expression	  
data	  for	  each	  gene.	  It	  uses	  emperical	  Bayes	  method	  to	  moderate	  the	  standard	  errors	  of	  the	  
estimated	   log	  fold	  changes.	  Benjamini-­‐Hochberg	  test	  was	  used	  for	  multiple	  correction	  and	  
genes	  with	  False	  Discovery	  Rate	  (FDR)	  <	  0.05	  were	  considered	  to	  be	  differentially	  expressed.	  
Since	   Gse27342	   represents	   paired	   data,	   paired	   Limma	   test	   for	   was	   used	   for	   its	   analysis.	  
Functional	   enrichment	   of	   Differentially	   Expressed	   Genes	   (DEG),	   common	   among	   the	   2	  
datasets	  was	  performed	  by	  submitting	  entrez	  ids	  of	  DEG	  to	  the	  ToppFun	  tool	  [168].	  	  
5.3.3 Connectivity Map Analysis 
Entrez	   gene	   identifiers	   of	   DEG	   from	   the	   microarray	   datasets	   were	   mapped	   to	  
Affymetrix	  HG-­‐U133A	  probesets	  using	  hgu133a.db	  package	  [169]	   in	  R.	  For	  analysis	  of	  each	  
microarray	   study,	   lists	   of	   DEG	   of	   size	   “k”	  were	   used	   as	   input	   query	   to	   CMap	   (version	   2),	  
where	   “k”	   was	   varied	   from	   400,	   to	   1000,	   using	   an	   increment	   of	   200.	   Compounds	   with	  
negative	  enrichment	  scores	  at	  permutation	  P-­‐value	  <	  0.05	  from	  each	  iteration	  were	  selected	  
to	   identify	   compounds	   which	   can	   maximally	   reverse	   the	   gene	   signature.	   Intersection	   of	  




	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
	  
Figure 5-1. Overview of the methodology. 
	  
5.4 Results 
5.4.1 Gastric Cancer Data Analysis 
The	  number	  of	  Differentially	  Expressed	  Genes	  (DEG)	   in	  each	  dataset	   is	  summarized	  
in	   Table	   5-­‐2.	   Venn	   diagram	  of	   DEG	   common	   between	   the	   two	   gastric	   cancer	   data	   sets	   is	  
shown	   in	   Figure	   5-­‐2.	   There	  were	   468	   up-­‐regulated	   genes	   and	   204	   down-­‐regulated	   genes	  
that	  were	  differentially	  expressed	  in	  both	  the	  two	  datasets.	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   Number	  of	  Differentially	  Expressed	  Genes	  (DEG)	  
	   Up-­‐regulated	   Down-­‐regulated	  
Gse27342	  (n=160)	   652	   341	  
Gse13861	  (n=84)	   3366	   2329	  
GSE14210	  (n=44)	   12481	   3	  
Table 5-2. Number of Differentially Expressed Genes (DEG) in gastric cancer datasets. n = sample size. 
	  
  
Figure 5-2. Venn diagram showing intersection between Differentially Expressed Genes (DEG) from the 
two gastric cancer datasets. 
	  
5.4.2 Connectivity Map Analysis 
To	  identify	  potential	  compounds	  that	  can	  maximally	  reverse	  the	  gastric	  cancer	  gene	  
signature	   identified	   above,	   Connectivity	   Map	   was	   used.	   Probes	   corresponding	   to	   the	  
upregulated	   and	   downregulated	   genes	   were	   used	   as	   input	   query	   for	   CMap.	   However,	  
Up-­‐regulated	  Genes	   Down-­‐regulated	  Genes	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instead	  of	  using	  standard	  input	  list	  of	  top	  500	  up-­‐regulated	  and	  500	  down-­‐regulated	  genes,	  
we	  submitted	  four	  lists	  of	  DEG	  of	  different	  sizes.	  List	  of	  DEG	  of	  size	  “k”	  were	  used	  as	  input	  
query	   to	   CMap,	   where	   “k”	  was	   varied	   from	   400	   to	   1000,	   with	   increment	   of	   200	   in	   each	  
iteration.	   The	   CMap	   results	   for	   gastric	   cancer	   dataset	   GSE27342	   and	   GSE13861	   are	  
summarized	   in	   Table	   5-­‐3.	   The	   role	   of	   these	   compounds	   in	   gastric	   and	   other	   cancers	   are	  
summarized	   in	   Table	   5-­‐4.	   Four	   out	   of	   the	   eleven	   compounds	   identified	   by	   our	   appraoch,	  
have	   been	   shown	   to	   have	   implications	   in	   gastric	   cancer	   in-­‐vivo	   or	   in-­‐vitro	   studies.	  
Vorinostat,	  trichostatin	  A	  and	  thiostrepton	  are	  the	  compounds	   identified	  with	  both	  gastric	  
cancer	  datasets.	  Vornistat	   is	  currently	  being	  tested	  in	  clinical	  trials	  for	  treatment	  of	  gastric	  
cancer	   –	   i)	   in	   combination	   with	   Capecitabine	   and	   Cisplatin	   for	   1st	   line	   of	   treatment	   of	  
metastatic	   or	   recurrent	   gastric	   cancer	   [ClinicalTrials.gov	   ID:	   NCT01045538].	   ii)	   with	  
irinotecan,	   fluorouracil,	   and	   leucovorin	   in	   treating	   patients	   with	   advanced	   upper	  
gastrointestinal	  cancer	  [ClinicalTrials.gov	  ID:	  	  NCT00537121].	  
The	  DEG	   in	   gastric	   cancer	   identified	   above	  were	   enriched	   for	  GO	   (Gene	  Ontology)	  
biological	   processes	   and	   pathways	   using	   ToppFun.	   Topmost	   pathways	   enriched	   for	   DEG	  
from	   GSE27342	   included	   cell	   cycle,	   extracellular	   matrix	   organisation,	   RB	   in	   cancer	   and	  
collagen	   formaton.	   Genes	   from	   each	   pathway	   were	   submitted	   to	   CMap	   separately	   to	  
identify	   compounds	   that	   can	   reverse	   the	   expression	   of	   genes	   representing	   the	   enriched	  





GSE27342	   GSE13861	  
vorinostat*	   vorinostat*	  
trichostatin	  A*	   trichostatin	  A*	  
thiostrepton	   thiostrepton	  
phenoxybenzamine	   scriptaid	  
resveratrol*	   gossypol*	  
monobenzone	   	  
antimycin	  A	   	  
bufexamac	   	  
0175029-­‐0000	   	  
Table 5-3. List of the compounds predicted by CMap for each gastric cancer dataset. The compounds 
highlighted in bold and with asteric have been reported in literature to have implications in gastric cancer at in-
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CDK	  inhibitor	  
	  
	   	  


























Table 5-4. Characteristics of CMap compounds that have expression profiles opposite to that of gastric 




RB	  in	  Cancer	   Collagen	  formation	  
phenoxybenzamine	   verteporfin	   phenoxybenzamine	   amrinone	  
tanespimycin	   CP-­‐690334-­‐01	   tanespimycin	   CP-­‐690334-­‐01	  
Thioguanosine	   Prestwick-­‐675	   Thioguanosine	   PNU-­‐0293363	  
Apigenin	   moracizine	   Apigenin	   merbromin	  
pyrvinium	   cicloheximide	   pyrvinium	   iopamidol	  




5.4.3 Acquired Resistance to Cisplatin and Flurouracil in Gastric Tumors 
One	   of	   the	   key	   challenges	   in	   cancer	   treatment	   is	   development	   of	   resistance	   to	  
chemotherapy.	  To	  address	  this	  challenge,	  we	  analyzed	  GSE14210	  data	  to	  identify	  the	  genes	  
and	  pathways	  differentially	  regulated	  in	  tumors	  which	  had	  acquired	  resistance	  to	  Cisplatin-­‐
Flurouaracil	  (CF).	  Four	  lists	  of	  DEG	  of	  size	  400,	  600,	  800	  and	  1000	  were	  run	  through	  CMap	  
and	   intersection	   of	   compounds	   from	   the	   four	   iterations	   identified	   29	   compounds.	  
Trichostatin	  A,	  identified	  through	  the	  CMap	  approach	  has	  previously	  been	  shown	  to	  induce	  
sensitivity	  to	  cisplatin	  treatment	  in	  cisplatin-­‐resistant	  human	  lung	  adenocarcinoma	  cell	  line	  
(A549	  cells)	  [189].	  	  
Most	   of	   the	   DEG	   were	   over-­‐expressed	   (12,481)	   and	   only	   3	   genes	   were	   under-­‐
expressed.	   Functional	   enrichment	  of	  DEG	   identifed	   two	  major	  pathways	   –	   statin	  pathway	  
and	  metabolism	  pathway	   (including	  metabolism	  of	   lipids	   and	   lipoproteins,	   The	   Citric	   Acid	  
(TCA)	   cycle	   and	   respiratory	   electron	   transport	   and	   metabolism	   of	   amino	   acids	   and	  
derivatives)	   Table	   5-­‐6.	   Two	   independent	   studies	   have	   shown	   that	   fatty	   acid	   synthesis	  
pathway	  contributes	  to	  resistance	  to	  cisplatin	  [190]	  and	  to	  flurouracil	  [191]	  in	  breast	  cancer	  
cells.	  GLUD1,	  GLUD2	  -­‐	  genes	  that	  code	  for	  enzymes	  involved	  in	  glutaminolysis	  (conversion	  of	  
the	  amino	  acid	  glutamine	   to	  α-­‐ketoglutarate)	  were	  also	  differentially	  expressed	   in	   the	  CF-­‐
resistant	  tumor	  as	  compared	  to	  CF-­‐sensitive	  tumors.	  Cancer	  cells	  have	  been	  reported	  to	  be	  
dependent	   on	   glutamine	   to	   maintain	   TCA	   cycle	   [192].	   Glutaminolysis	   co-­‐induced	   by	  
glutamine	  and	  leucine	  can	  activate	  mTORC1	  signaling,	  which	  triggers	  cell	  growth	  and	  inhibits	  
autophagy	   [193].	  Further	  study	  of	   the	  DEG	   involved	   in	  statin	  and	  metabolic	  pathways	  can	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elucidate	   the	   possible	   mechanism	   by	   which	   the	   gastric	   tumors	   developed	   resistance	   to	  























    Table 5-6. Pathway enrichment for genes differentially expressed in cisplatin-  resistant tumors. 
5.5 Limitations 
Although	  Connectivity	  Map	  is	  a	  unique	  and	  powerful	  strategy	  to	  use	  genomic	  disease	  
signature	   to	   for	   drug	   repurposing,	   it	   has	   a	   few	   limitations.	   The	   therapeutic	   compounds	  
identified	   are	   limited	   to	   the	   compounds	   present	   in	   CMap	   library.	   Secondly,	   CMap	   uses	   a	  
simple	   algorithm	   to	   represent	   degree	   of	   connectiveness	   between	   the	   query	   disease	  
signature	  and	  the	  compound	  signature.	  This	  algorithm	  has	  been	  useful	  in	  a	  number	  of	  cases,	  
but	  it	  may	  not	  be	  the	  most	  productive	  representation	  of	  connectivity.	  However,	  it	  is	  possible	  
for	  the	  users	  to	  implement	  an	  advanced	  algorithm	  and	  scoring	  criteria	  by	  using	  original	  gene	  
expression	  data	  for	  the	  CMap	  compounds.	  In	  addition,	  it	  is	  unclear	  to	  how	  a	  drug’s	  potential	  
in	  breast	  cancer,	  prostrate	  cancer,	  melanoma	  and	   leukemia	  cell	   lines,	  which	  were	  used	  to	  
generate	  CMap	  signatures,	  will	   be	   relevant	   in	  gastric	   cancer.	  However,	   there	   is	   a	   growing	  
evidence	   of	   success	   rate	   of	   identifying	   potential	   therapeutic	   compounds	   from	   CMap	   for	  





• Analysis	  of	  gene	  expression	  profiles	  from	  multiple	  disease	  datasets	  can	  help	  to	  identify	  
important	  pathways	  and	  potential	  novel	  therapeutic	  targets	  for	  the	  disease.	  
• Connectivity	  Map	  helps	  to	   identify	  and	  prioritize	  existing	  drugs	  or	  compounds	  that	  can	  
be	  of	  therapeutic	  value	  for	  the	  disease.	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In	  Chapter	  3,	  qPCR	  data	  from	  uninfected	  and	  H.	  pylori	  infected	  -­‐	  wild	  type	  and	  PC-­‐SHH-­‐
KO	   mice,	   was	   analyzed.	   The	   statistical	   analysis	   suggests	   that	   Sonic	   Hedgehog	   (SHH)	  
positively	   regulates	   expression	   of	   cytokines	   like	   IL-­‐12,	   IL-­‐1β,	   MIP-­‐2,	   IL-­‐10,	   however	   the	  
mechanism	  remains	  unclear.	  We	  developed	  a	  simple	  mathematical	  model	  of	  the	  cytokines	  
and	  SHH	  activated	  during	  H.	  pylori	  infection.	  Our	  model	  captures	  the	  positive	  regulation	  of	  
cytokines	   by	   SHH	   through	   an	   intermediate	  model	   species	   ‘X’.	  We	   speculate	   the	   following	  
mechanism	   through	  which	   SHH	  may	   play	   a	   key	   role	   in	   regulating	   the	   cytokines	   during	  H.	  
pylori	   infection.	   Schumacher	   et	   al	   have	   shown	   that	   SHH	   acts	  as	  
a	  macrophage	  chemoattractant	  in	  response	  to	  H.	  pylori	  infection	  [111]	  and	  this	  mechanism	  
involves	  smoothened	  receptor,	  which	  is	  downstream	  of	  SHH	  signaling.	  It	  has	  been	  reported	  
by	  independent	  studies	  that	  monocytes	  and	  macrophages	  treated	  with	  H.	  pylori	  secrete	  IL-­‐
1β,	   IL-­‐12,	   IL-­‐10,	   TNFγ,	   IL-­‐6	   [131–133].	   Thus	   the	   positive	   influence	   on	   the	   expression	   of	  
cytokines	   by	   SHH,	   predicted	   by	   our	   qPCR	   data	  may	   be	  mediated	   through	   recruitment	   of	  
macrophage	  by	  SHH	  to	  the	  gastric	  epithelium.	  The	  IL-­‐12	  secreted	  in	  turn	  activates	  release	  of	  







SHH	  can	  enhance	  the	  expression	  of	  cytokines	  like	  IL-­‐12,	  IL-­‐1β,	  MIP2	  (CXCL-­‐2)	  and	  TNF	  
in	   H.	   pylori	   stimulated	   macrophages	   and	   this	   mechanism	   involves	   smoothened	   receptor	  
(SMO).	  	  
6.2.2 Significance 
Results	   from	   this	   experiment	   can	   help	   to	   identify	   unknown	   molecule	   ‘X’	   in	   our	  
mathematical	  model	   and	   reduce	   the	  existing	  knowledge	  gap	  between	  SHH	  and	  cytokines,	  
which	  are	  activated	  during	  H.	  pylori	  infection.	  	  	  
6.2.3 Expected Results: 
In WT group, macrophages stimulated with SHH would express higher levels of 
cytokines as compared to that in macrophages stimulated with PBS. This would suggest that 
positive regulation of cytokines by SHH involves macrophages. Whereas, (Smoothened 
gene knock-out) SMO-KO macrophages stimulated with SHH would express lower levels of 
cytokines as compared to WT macrophages stimulated with SHH. This would suggest that 
SHH-SMO pathway is involved in cytokines production from macrophages. 
 
6.3 Materials and Methods 
6.3.1 Cell Culture 
H.	  pylori	  SS1	  (kindly	  donated	  by	  Dr.	  K.	  A.	  Eaton,	  University	  of	  Michigan,	  Ann	  Arbor,	  
MI)	   bacteria	   were	   grown	   in	   Brucella	   broth	   supplemented	   with	   5%	   fetal	   calf	   serum	   in	   a	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humidified	   microaerophilic	   chamber	   (BBL	   Gas	   System,	   with	   CampyPak	   Plus	   packs;	   BD	  
Microbiology,	  Sparks,	  MD)	  in	  a	  shaking	  incubator	  at	  37oC	  for	  16	  hours.	  Macrophages	  were	  
generated	   from	   bone	   marrow	   (femur)	   of	   WT	   (LysMCre)	   and	   SMO-­‐KO	  
(LysMCre/SmoothenedFF)	  mice	   [111].	   Briefly,	   bone	  marrow	   from	   femur	   and	   tibia	   of	  mice	  
was	  isolated,	  filtered	  through	  a	  40	  micron	  sieve,	  and	  grown	  on	  12	  well-­‐plate	  containing	  1ml	  
of	  DMEM	  media	  (DMEM	  +	  1%	  penicillin	  +	  1%	  streptomycin	  +	  sodium	  pyruvate)	  and	  50	  ul	  of	  
MCSF	  (Macrophage	  Colony	  Stimulating	  Factor)	  media	  per	  well.	  After	  3	  days,	  non-­‐adherent	  
cells	   were	   removed	   and	   the	   remaining	   differentiated	   macrophages	   were	   used	   for	  
experimentation.	  Cells	  were	  incubated	  with	  a	  10:1	  multiplicity	  of	  infection	  (MOI)	  of	  H.	  pylori	  
(Sydney	   strain	   1)	   for	   2	   hours.	   WT	   macrophages	   were	   divided	   into	   two	   groups,	   one	   was	  
stimulated	  with	  1ug/ml	  SHH	  (n=4)	  and	  other	  with	  PBS	  (n=4)	  for	  10	  hours.	  Similarly,	  SMO-­‐KO	  
macrophages	   were	   stimulated	   either	   with	   SHH	   (n=4)	   or	   by	   PBS	   (n=4)	   for	   10	   hours.	  
Previously,	  macrophages	  were	  also	  treated	  with	  only	  SHH,	  without	  pre-­‐stimulation	  with	  H.	  
pylori	   and	   tested	   for	   expression	   of	   cytokines.	   These	   macrophages	   did	   not	   express	   the	  
cytokines	   in	  absence	  of	  H.	  pylori	   stimulation.	  Currently,	   there	   is	  no	   literature	  studying	   the	  
effect	  of	  SHH	  treatment	  on	  macrophages	  that	  could	  be	  used	  as	  a	  reference.	  We	  estimated	  
10	  hours	  of	  SHH	  exposure	  time	  based	  on	  a	  study	  that	  showed	  production	  of	  cytokines	  (IL-­‐
12)	  from	  dendritic	  cells	  within	  10	  hours	  of	  treatment	  with	  H.	  pylori	  [194].	  	  
6.3.2 Quantitative Real-Time PCR (qPCR) 
Total	   RNA	   was	   isolated	   from	   the	   macrophages	   and	   High	   Capacity	   cDNA	   Reverse	  
Transcription	   Kit	   was	   used	   for	   cDNA	   synthesis	   from	   100ng	   of	   RNA	   following	   the	  
manufacturer’s	   protocol	   (Applied	   Biosystems).	   Predesigned	   real-­‐time	   PCR	   assays	   were	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purchased	  for	  the	  following	  genes	  (TaqMan	  Gene	  Expression	  Systems;	  Applied	  Biosystems):	  
IL-­‐12,	  MIP2,	  IL-­‐1Β,	  and	  HPRT.	  HPRT	  was	  used	  as	  an	  internal	  control.	  PCR	  amplifications	  were	  
performed	  in	  a	  total	  volume	  of	  20	  uL	  containing	  20X	  TaqMan	  Expression	  Assay	  primers,	  2X	  
TaqMan	  Universal	  Master	  Mix	  (TaqMan	  Gene	  Expression	  Systems;	  Applied	  Biosystems),	  and	  
complementary	  DNA	  template.	  Each	  PCR	  amplification	  was	  performed	  in	  duplicate	  wells	  in	  a	  
StepOne	  Real-­‐Time	  PCR	   System	   (Applied	  Biosystems)	   using	   the	   following	   conditions:	   50°C	  
for	  2	  minutes,	  95°C	  for	  10	  minutes,	  95°C	  for	  15	  seconds	  (denature),	  and	  60°C	  for	  1	  minute	  
(anneal/extend)	  for	  40	  cycles.	  	  
6.3.3 Statistical Analysis 
For	  each	  sample,	  dCT	  value	  for	  target	  gene	  was	  calculated	  by	  subtracting	  CT	  value	  of	  
calibrator	  gene	  (HPRT)	  from	  CT	  value	  of	  target	  gene.	  To	  test	  if	  expression	  of	  the	  cytokines	  in	  
H.	  pylori	  stimulated	  macrophages	  was	  affected	  by	  SHH,	  a	  t-­‐test	  was	  performed.	  dCT	  values	  
from	  PBS	  treated	  WT	  macrophages	  were	  compared	  with	  dCT	  values	  from	  SHH	  treated	  WT	  
macrophages.	   P-­‐value	   <0.05	   was	   considered	   statistically	   significant.	   For	   graphical	  
presentation	  of	  qPCR	  results,	  for	  each	  gene,	  ddCT	  was	  calculated	  by	  subtracting	  dCT	  value	  of	  
SHH	   treated	   group	   from	   dCT	   of	   PBS	   treated	   group.	   The	   data	  were	   plotted	   as	   2-­‐ddCT	   (fold	  
change).	  The	  qPCR	  data	  was	  analyzed	  using	  R	  statistical	  software.	  	  
6.4 Results 
H.	  pylori	  stimulated	  macrophages	  were	  treated	  with	  SHH	  or	  PBS	  and	  expression	  of	  IL-­‐
12,	   IL-­‐b,	   MIP2	   (CXCL2)	   and	   TNF	   were	   measured	   by	   qPCR.	   No	   statistically	   significant	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difference	   was	   observed	   in	   the	   expression	   of	   cytokines	   between	   SHH	   and	   PBS	   treated	  
groups.	  
	  	  
	  	  	  	  	  	  	  	  	  	  	   	  
Figure 6-1. Effect of SHH on the expression of cytokines in H. pylori stimulated macrophages. 
	  
6.5 Conclusion 
Our	   current	   results	   show	   that	   there	   is	   not	   enough	   evidence	   to	   reject	   the	   null	  
hypothesis	  that	  -­‐	  SHH	  does	  not	  enhance	  the	  expression	  of	  cytokines	   like	   IL-­‐12,	   IL-­‐b,	  CXCL2	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and	   TNF	   in	  H.	  pylori	   stimulated	  macrophages.	  However,	   optimization	  of	   the	   experimental	  
design	  may	  be	  required	  to	  further	  explore	  the	  role	  of	  SHH	  in	  regulation	  of	  these	  cytokines.	  
For	  example,	   further	  optimization	  of	   time	  period	   for	  which	  macrophages	  are	   treated	  with	  
SHH	  and	   the	  SHH	  concentration	  used,	  may	  allow	   to	  better	  understanding	  of	   the	  effect	  of	  
SHH	  on	  cytokines’	  expression	  and	  their	  release	  from	  macrophages.	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Chapter 7: Using empirical probability (frequency) of change for 
analyzing microarray data. 
This	   chapter	   describes	   the	   framework	   of	   integrating	   (i)	   probability	   (frequency)	   of	  
change,	  (ii)	  fold	  change	  and	  (iii)	  pathway	  knowledge	  for	  identifying	  disease	  biomarkers	  form	  
microarray	  data.	  We	  discuss	  the	  advantages	  and	  limitations	  of	  the	  proposed	  method.	  	  
7.1 Background and Motivation 
Gastric	  cancer	   is	   the	  3rd	   leading	  cause	  of	  cancer-­‐related	  deaths	  worldwide.	  The	   five-­‐
year	  survival	  rate	  for	  the	  disease	  is	  high	  (71-­‐57%)	  if	  diagnosed	  in	  early	  stage	  as	  compared	  to	  
that	  in	  late	  stages	  (20-­‐4%)	  [3].	  The	  two	  major	  factors	  contributing	  to	  the	  low	  survival	  rate	  of	  
gastric	   cancer	   are	   late	   diagnosis	   due	   to	   lack	   of	   diagnostic	   biomarkers	   and	   limited	   target	  
based	   drugs	   available	   for	   treatment	   of	   the	   disease.	   Identification	   of	   genes	   and	   pathways	  
that	  are	  differentially	  regulated	  in	  gastric	  cancer	  is	  critical	  for	  discovery	  of	  new	  biomarkers	  
and	   drug	   targets	   for	   the	   disease.	   One	   of	   the	   major	   challenges	   while	   comparing	   gene	  
expression	   between	   tissues	   obtained	   from	   cancer	   patients	   and	   healthy	   people	   is	   the	  
difference	  contributed	  by	  genetic	  heterogeneity	  among	  individuals.	  Thus,	  we	  selected	  only	  
those	   datasets	   from	   GEO	   database,	   where	   both	   tumor	   and	   (adjacent)	   non-­‐tumor	   tissues	  
were	  obtained	  from	  the	  same	  patient,	  thus	  reducing	  the	  error	  due	  to	  genetic	  heterogeneity	  
among	  individuals.	  	  
Currently,	  selection	  of	  differentially	  expressed	  genes	  relies	  heavily	  on	  the	  magnitude	  
of	   fold	   change	   of	   the	   gene	   in	   disease	   to	   that	   in	   control.	   The	   standard	   process	   involves	  
comparison	   of	   control	   and	   treatment	   group	   by	   a	   parametric	   or	   non-­‐parametric	   statistical	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test,	   followed	   by	   selection	   of	   genes	   with	   adjusted	   p-­‐value	   <	   0.05.	   The	   genes	   are	   further	  
sorted	   and	   selected	   based	   on	   their	   fold	   change.	   However,	   some	   genes,	   like	   transcription	  
factors	   that	   can	   play	   a	   crucial	   role	   in	   disease,	  may	   exhibit	   low	   fold	   change	   in	   expression	  
[195].	  So,	  we	  suggest	  integrating	  two	  other	  features	  while	  selecting	  differentially	  expressed	  
genes	  –	  (i)	  consistency	  (frequency)	  of	  change	  across	  the	  sample	  population.	  (ii)	  topological	  
network	  of	  biological	  pathways.	  	  
7.2 Hypothesis 
Integration	  of	  ‘frequency	  of	  change’	  in	  gene	  expression	  and	  pathway	  knowledge	  along	  
with	   fold	   change	   can	   enhance	   the	   method	   of	   screening	   the	   list	   of	   DEG	   (differentially	  
expressed	  genes)	  identified	  based	  on	  FDR	  statistics	  than	  using	  only	  fold	  change	  criteria.	  
7.3 Methods 
7.3.1 Datasets 
Three	  microarray	  data	  sets	  with	  gastric	   tumor	  and	  adjacent	  non-­‐tumor	  tissues,	  are	  
obtained	   from	  GEO	   [166]	   database	   -­‐	   GSE27342	   (n=160),	   GSE3438	   (n=100)	   and	   GSE13861	  
(n=84).	   For	   each	   data	   set,	   patients	   are	   randomly	   divided	   into	   training	   and	   test	   set	   using	  
three	  fold	  cross	  validation	  approach.	  Two-­‐third	  of	  the	  patients	  are	  assigned	  to	  training	  set	  
and	  one-­‐third	  to	  test	  set	  and	  this	  process	  is	  repeated	  3	  times,	  with	  each	  of	  the	  3	  subsamples	  
of	   patients	   used	   exactly	   once	   as	   the	   test	   set.	   Differentially	   expressed	   genes	   (DEG)	   are	  
predicted	  using	  training	  set	  and	  then	  the	  error	  rate	  for	  the	  prediction	  is	  calculated	  using	  test	  
set.	   The	   estimated	   errors	   from	   the	   three	   iterations	   are	   averaged	   to	   calculate	   overall	   F1	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score	  and	  AUROC	  (Area	  Under	  Receiver	  Operating	  Characteristic).	  Plotting	  Recall	  over	  False	  
Positive	  Rate	  creates	  ROC	  curve	  and	  AUROC	  value	  above	  0.8	  is	  considered	  good	  while	  value	  
less	  than	  0.6	   is	  considered	  as	  poor	  performance	  of	  the	  algorithm.	  The	  advantage	  of	  k-­‐fold	  
method	   over	   repeated	   random	   sub-­‐sampling	   is	   that	   all	   observations	   are	   used	   for	   both	  
training	  and	  validation,	  and	  each	  observation	  is	  used	  for	  validation	  exactly	  once.	  	  
𝐹1 =      2   ∗   Precision   ∗   RecallPrecesion+ Recall   	  
𝑃𝑟𝑒𝑐𝑖𝑠𝑖𝑜𝑛 =    𝑇𝑟𝑢𝑒  𝑃𝑜𝑠𝑖𝑡𝑖𝑣𝑒  𝑇𝑟𝑢𝑒  𝑃𝑜𝑠𝑖𝑡𝑖𝑣𝑒 + 𝐹𝑎𝑙𝑠𝑒  𝑃𝑜𝑠𝑖𝑡𝑖𝑣𝑒	  
𝑅𝑒𝑐𝑎𝑙𝑙 =    𝑇𝑟𝑢𝑒  𝑃𝑜𝑠𝑖𝑡𝑖𝑣𝑒𝑇𝑟𝑢𝑒  𝑃𝑜𝑠𝑖𝑡𝑖𝑣𝑒 + 𝐹𝑎𝑙𝑠𝑒  𝑁𝑒𝑔𝑎𝑡𝑖𝑣𝑒	  
𝐹𝑎𝑙𝑠𝑒  𝑃𝑜𝑠𝑖𝑡𝑖𝑣𝑒  𝑅𝑎𝑡𝑒 =    𝐹𝑎𝑙𝑠𝑒  𝑃𝑜𝑠𝑖𝑡𝑖𝑣𝑒  𝐹𝑎𝑙𝑠𝑒  𝑃𝑜𝑠𝑖𝑡𝑖𝑣𝑒 + 𝑇𝑟𝑢𝑒  𝑁𝑒𝑔𝑎𝑡𝑖𝑣𝑒	  
	  
7.3.2 Calculation of Frequency Score 
We	   first	   calculate	   log	   expression	   ratio	   (tumor	   expression/normal	   expression)	   for	   each	  
gene	   in	   each	   patient.	   Let	   aij	   represent	   log	   expression	   ratio	   (tumor	   expression/normal	  
expression)	   for	   gene	   ‘i’	   in	   patient	   ‘j’.	   For	   each	   gene,	   calculate	   the	   number	   of	   times	   aij	   is	  
greater	  than	  or	  less	  than	  zero	  and	  the	  associated	  p-­‐value	  using	  Binomial	  test.	  	  
For each gene, calculate aij in all patients: 
• Frequency.Increase = number of times aij > 0  
• Frequency.Decrese = number of times aij < 0 
• p-value (Binomial test) 
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If	   the	   p-­‐value	   for	   the	   gene	   is	   less	   than	   0.05,	   Frequency	   Score	   for	   that	   gene	   is	   assigned	   a	  
value	  that	   is	  greater	  between	  Frequency.Increase	  and	  Frequency.Decrease.	  The	  Frequency	  
Score	   is	  multiplied	  by	   -­‐1	   if	   Frequency.Decrease	   is	   greater	   than	   Frequency.Increase.	  Genes	  
with	  p-­‐value	  greater	  than	  0.05	  are	  given	  a	  Frequency	  Score	  of	  zero.	  	  
7.3.3 Calculation of Fold Score 
For	  each	  data	  set,	  we	  compare	  gene	  expression	  between	  gastric	  tumor	  and	  adjacent	  
non-­‐tumor	   tissue	   using	   Limma	   package	   in	   R.	   Since	   our	   data	   sets	   contain	   paired	   samples,	  
paired	   Limma	   test	   is	   used	   for	   the	   analysis.	   Benjamini-­‐Hochberg	   test	   is	   used	   for	   multiple	  
correction	   and	   genes	   with	   False	   Discovery	   Rate	   (FDR)	   <	   0.05	   are	   considered	   to	   be	  
differentially	  expressed.	  For	  genes	  with	  FDR	  <	  0.05,	  the	  log	  fold	  change	  is	  normalized	  such	  
that	  it’s	  value	  varies	  between	  0	  to	  1	  and	  can	  be	  easily	  integrated	  with	  Frequency	  Score	  later.	  
Maximum	   (logFCmax)	   and	   minimum	   (logFCmin)	   log	   fold	   change	   shown	   by	   all	   genes	   is	  
calculated.	  Normalized	  log	  fold	  change	  for	  each	  gene	  (Norm.logFCi)	  is	  calculated	  by	  dividing	  
the	  log	  fold	  change	  for	  that	  gene	  by	  the	  absolute	  value	  of	  the	  difference	  between	  logFCmax	  
and	   logFCmin.	   For	   genes	   with	   FDR	   >	   0.05,	   Norm.logFCi	   is	   assigned	   a	   value	   of	   zero.	   A	  
Cumulative	   Score	   is	   calculated	   for	   each	   gene	   by	   adding	   Frequency	   Score	   and	  Normalized	  
Fold	  Score	  of	  that	  gene.	  
7.3.4 Integration of Frequency of change and Fold change with pathways knowledge 
In	   future,	   the	   Fold	   Score	   and	   Frequency	   Score	   can	   be	   combined	   with	   biological	  
networks	   to	   identify	   differentially	   expressed	   pathways.	   Topological	   network	   of	   protein-­‐
protein	   interactions	   can	   be	   obtained	   from	   pathway	   databases	   like	   pathway	   commons,	  
reactome	   and	   NCI-­‐PID.	   The	   network	   nodes	   representing	   genes	   will	   be	   assigned	   the	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Cumulative	   Score	   calculated	   above.	   	   The	   central	   idea	  of	   this	   approach	   is	   -­‐	   the	  probability	  
that	   a	   gene	   is	   showing	   differential	   expression	   just	   by	   chance,	   is	   less	   if	   it	   is	   connected	   to	  
other	   differentially	   expressed	   genes	   and	   thus	   it	   gets	   higher	   ranking	   (score).	   	   Along	   with	  
frequency	   and	   fold	   change,	   inclusion	   of	   this	   approach	  would	   also	   take	   into	   account	   -­‐	   the	  
direction	  of	  change	  (overexpression	  or	  under-­‐expression)	  and	  pathway	  topology.	  
7.4 Preliminary Results 
Figure	   7-­‐1	   shows	   the	   differentially	   expressed	   genes	   predicted	   for	   160	   samples	   of	  
GSE27342.	   The	   top	  panel	   in	   blue	   shows	   genes	   that	  were	   predicted	   as	  DEG	  by	   frequency-­‐
based	  method	  but	  not	  by	  Limma.	  The	  second	  panel	  shows	  that	  there	  were	  two	  genes	  that	  
were	   predicted	   to	   be	   DEG	   by	   Limma	   but	   were	   missed	   by	   frequency-­‐based	   method.	   The	  
bottom	  panel	  in	  green	  shows	  the	  genes	  predicted	  to	  be	  DEG	  by	  both	  the	  methods.	  Although	  
frequency-­‐based	   approach	   captures	  more	   genes	   (which	  may	   include	  more	   True	  Positives)	  
than	  fold	  change	  method,	  it	  comes	  with	  a	  cost	  of	  increased	  noise	  (may	  include	  more	  False	  
Positives).	   So,	  we	  combine	   the	   two	  approaches	   to	   identify	  genes	   that	   change	  consistently	  
across	  the	  sample	  population	  and	  with	  high	  fold	  change.	  	  
7.5 Limitations 
Currently,	   the	   frequency-­‐based	  method	  does	  not	   incorporate	  correction	   for	  multiple	  
testing	  (for	  the	  p-­‐values	  that	  are	  calculated	  by	  Binomial	  test).	  In	  future,	  FDR	  method	  should	  
to	  be	  incorporated	  to	  calculate	  adjusted	  p-­‐values	  for	  all	  the	  genes.	  Although,	  the	  frequency	  
of	  change	  can	  be	  a	  useful	   feature	  along	  with	  fold-­‐change	  to	  further	  screen	  the	   list	  of	  DEG	  
113	  
	  
identified	  based	  on	  FDR	  statistics,	  this	  approach	  is	  limited	  to	  datasets	  that	  have	  large	  sample	  
size	  and	  contain	  paired	  samples.	  
	  
	  
Figure 7-1. Differentially expressed genes predicted by Limma and frequency-based approach.   
A) Genes predicted as DEG exclusively by frequency-based method B) Genes predicted as DEG exclusively by 






(C).	   Genes	   predicted	   by	  
both	  the	  methods.	  
(B).	   Genes	   predicted	   by	  
Limma	   but	   not	   by	  
frequency-­‐based	  method.	  	  
(A).	   Genes	   predicted	   by	  
frequency-­‐based	   method	  
but	  not	  by	  Limma.	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Chapter 8: Discussion 
	  
Gastric	  cancer	   is	   the	   fifth	  most	  common	  malignancy	   in	   the	  world	  and	  third	   leading	  
cause	  of	  cancer-­‐related	  mortality	  worldwide	  [1],	  with	  five-­‐year	  survival	  rate	  of	  only	  20-­‐29%	  
[3].	   In	   order	   to	   develop	   better	   drugs,	   diagnostics	   and	   preventive	   measures	   for	   gastric	  
cancer,	   it	   is	   critical	   to	   understand	   the	   underlying	   molecular	   biology	   of	   the	   disease	   and	  
factors	  that	  increase	  the	  risk	  for	  the	  disease.	  Helicobacter	  pylori-­‐induced	  atrophic	  gastritis	  is	  
a	  major	   risk	   factor	   associated	   with	   gastric	   cancer	   development	   [7].	  H.	   pylori	   infection	   of	  
gastric	  tissue	  results	  in	  an	  immune	  response	  dominated	  by	  Th1	  cytokines	  [96]	  and	  has	  also	  
been	   linked	  with	  deregulation	  of	  Sonic	  Hedgehog	  (SHH)	  signaling	  pathway	   in	  gastric	  tissue	  	  
[110,111].	   However,	   a	  model	   studying	   temporal	   relationship	   between	   SHH	   and	   cytokines	  
activated	   during	  H.	   pylori	   infection	   is	   lacking.	   Also,	   the	  molecular	   details	   that	   link	   gastric	  
cancer	  and	  H.	  pylori	  mediated	  atrophic	  gastritis	  are	  not	  well	  understood.	  	  
The	  objective	  of	  this	  dissertation	  research	  were:	  1)	  to	  study	  the	  cytokine-­‐SHH	  sub-­‐network	  
activated	  during	  H.	  pylori	  infection.	  2)	  to	  identify	  the	  molecular	  signature	  common	  to	  gastric	  
cancer	  and	  H.	  pylori	  mediated	  	  atrophic	  gastritis.	  3)	  drug	  repurposing	  for	  gastric	  cancer.	  We	  
have	  used	  mathematical	  modeling	  and	  publically	   available	  microarray	  data	   to	  explore	   the	  
temporal	  behavior	  of	   the	  cytokine-­‐SHH	  subnetwork,	  which	  plays	  a	  critical	   role	   in	  H.	  pylori	  
mediated	  gastritis.	  We	  also	  identified	  genes	  and	  pathways	  that	  are	  differentially	  expressed	  
in	   gastric	   cancer	   and	  H.	   pylori	   mediated	   atrophic	   gastritis.	   We	   use	   signature-­‐based	   drug	  




8.1 Mathematical modeling of cytokine-SHH sub-network in H. pylori 
infected gastric tissue.  
8.1.1 Summary of Major Findings 
Analysis	   of	   qPCR	   data	   from	   uninfected	   and	  H.	   pylori	   infected	   -­‐	  WT	   and	   PC-­‐SHHKO	  
mice,	  shows	  that	  SHH	  positively	  regulates	  expression	  of	  cytokines	  like	  IL-­‐12,	  IL-­‐1β,	  MIP-­‐2,	  IL-­‐
10,	  however	  the	  mechanism	  remains	  unclear.	  Our	  mathematical	  model	  suggests	  that	  NFĸB,	  
SHH	  and	  the	  cytokines	  engage	  in	  a	  feedback	  loop	  which	  can	  result	  in	  damped	  oscillations.	  
8.1.2 Significance of the findings 
Our analysis of experimental data indicates a positive regulation of the cytokines’ 
expression involving SHH. However, current pathway databases (for example Strings, 
Pathway Commons), and molecular circuits (wiring diagram of interactions among genes 
and proteins) derived through manual curation of current literature, fail to identify the positive 
regulation. The mathematical model helps to bring out emergent properties of the network, 
which can guide future experimental studies and enhance our current understanding of the 
system. We use the model as a tool to gain insights into cytokine and SHH relationship 
during H. pylori infection and as a hypotheses generating tool.  
8.1.3 Future Directions 
Temporal analysis of cytokines from an independent microarray dataset also indicates 
that IL-1β, IFNγ and IL-10 from H. pylori infected mice, show a cyclic behavior rather than a 
linear trend. Based on our preliminary results from analysis of Geo dataset, we propose that 
experiments capturing expression of cytokines and other genes at different time points (on 
scale of days) can inform about time dependent variation in expression of genes and also 




8.2 Meta-analysis of microarray data from gastric cancer and H. pylori 
infected patients. 
8.2.1 Summary of Major Findings 
Our	   analysis	   shows	   that	   cell-­‐cell	   adhesion,	   cell-­‐cell	   communication,	   tight	   junctions	  
and	   leukocyte	   transendothelial	  migration	   involving	   claudin	   genes	   (CLDN1,	   CLDN2,	   CLDN3,	  
CLDN4,	  CLDN7)	  are	  the	  key	  pathways	  that	  were	  up-­‐regulated	  in	  both	  gastric	  cancer	  and	  H.	  
pylori	   mediated	   atrophic	   gastritis.	   Whereas,	   genes	   involved	   in	   gastric	   acid	   secretion,	  
potassium	  ion	  transport	  and	  creatine	  pathways	  were	  down-­‐regulated	  in	  both	  the	  diseases.	  
8.2.2 Significance of the findings 
Although,	   atrophic	   gastritis	   accompanied	   with	   loss	   of	   parietal	   cells	   and	  
hypochlorhydria	   is	   highly	   associated	   with	   development	   of	   gastric	   cancer	   [165],	   the	  
molecular	  details	   that	   link	   gastric	   cancer	  and	  H.	  pylori	  mediated	  atrophic	   gastritis	   are	  not	  
well	   understood.	   Identification	   of	   genes	   and	   pathways	   which	   are	   dis-­‐regulated	   in	   both	  
gastric	  cancer	  and	  H.	  pylori	  mediated	  atrophic	  gastritis	  will	  enhance	  our	  current	  knowledge	  
about	  the	  molecular	  details	  which	  link	  the	  two	  diseases.	  
8.2.3 Future Directions 
Further	   analysis	   of	   the	   genes	   and	   pathways	   identified	   above	   can	   elucidate	   the	  
underlying	   molecular	   mechanism	   through	   which	   H.	   pylori	   mediated	   atrophic	   gastritis	  




8.3 Drug Repurposing for gastric cancer using gene expression data. 
8.3.1 Summary of Major Findings 
Genes	  upregulated	  in	  the	  two	  gastric	  cancer	  datasets	  were	  mostly	  enriched	  for	  cell	  
cycle	   pathways	   while	   the	   down-­‐regulated	   genes	   were	   enriched	   for	   pathways	   involved	   in	  
gastric	  acid	  secretion.	  Connectivity	  Map	  (CMap)	  analysis	   identified	  eleven	  compounds	  that	  
can	  potentially	  reverse	  the	  gastric	  cancer	  signatures	  dervied	  from	  the	  two	  disease	  data	  sets.	  
Vorinostat,	   trichostatin	   A	   and	   thiostrepton	   are	   the	   compounds	   that	   were	   identified	   with	  
both	  the	  datasets.	  	  
We	  also	  identified	  the	  genes	  and	  pathways	  differentially	  regulated	  in	  gastric	  tumors	  
which	   had	   acquired	   resistance	   to	   Cisplatin-­‐Flurouaracil	   (CF)	   chemotherapy.	   Functional	  
enrichment	  of	  differentially	  expressed	  genes	  identifed	  two	  major	  pathways	  –	  statin	  pathway	  
and	  metabolism	   pathway	   (including	  metabolism	   of	   lipids	   and	   lipoproteins,	   The	   citric	   acid	  
(TCA)	   cycle	   and	   respiratory	   electron	   transport	   and	   metabolism	   of	   amino	   acids	   and	  
derivatives).	   CMap	   analysis	   identified	   29	   compounds	   that	   can	   potentially	   reverse	   the	  
cisplatin-­‐flurouracil	  resistant	  signature.	  	  
8.3.2 Significance of the findings 
One	   of	   the	   approaches	   to	   reduce	   the	   high	   cost	   and	   time	   associated	   with	   drug	  
discovery	   is	  through	  repurposing	  of	  drugs	  approved	  for	  other	  diseases.	  The	  key	  advantage	  
of	   this	   approach	   is	   established	   safety	  profile	  of	   the	  drugs.	  We	  use	  molecular	   signature	  of	  
gastric	  cancer	  derived	  from	  microarray	  data	  and	  Broad	  Institute’s	  Connectivity	  Map	  (CMap)	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to	   identify	   and	   prioritize	   compounds	   that	   can	   be	   further	   tested	   in	   lab	   for	   treatment	   of	  
gastric	  cancer.	  	  
8.3.3 Future Directions 
In	   future,	   three	   fold	   cross	   validation	   approach	   can	   be	   used	   for	   identifying	  
differentially	  expressed	  genes;	   for	  each	  data	  set,	  patients	  would	  be	  randomly	  divided	   into	  
training	  and	  test	  set.	  Two-­‐third	  of	  the	  patients	  should	  be	  assigned	  to	  training	  set	  and	  one-­‐
third	   to	   test	   set	   and	   this	   process	   is	   repeated	   3	   times,	   with	   each	   of	   the	   3	   subsamples	   of	  
patients	   used	   exactly	   once	   as	   the	   test	   set.	   Differentially	   expressed	   genes	   (DEG)	   will	   be	  
predicted	   using	   training	   set	   and	   then	   the	   error	   rate	   for	   the	   prediction	   will	   be	   calculated	  
using	  test	  set.	  The	  estimated	  errors	  from	  the	  three	  iterations	  will	  be	  averaged	  to	  calculate	  
overall	   F1	   score	   and	   AUROC	   (Area	   Under	   Receiver	   Operating	   Characteristic).	   Along	   with	  
CMap,	  other	  resources	  for	  therapeutic	  compounds’	  genomic	  data	  can	  also	  be	  used	  –	  LINCS	  
(Library	   of	   Integrated	   Network-­‐based	   Cellular	   Signatures)	   [196],	   CCLE	   (Cancer	   Cell	   Line	  
Encyclopedia:	   24	   anticancer	   drugs	   across	   479	   cell	   lines)	   [197],	   caArray	   GSKdata	   (19	  
compounds	   in	   a	   panel	   of	   311	   cancer	   cell	   lines)	   [198].	   Integration	   of	   genomics	   data	   with	  
available	  signaling	  and	  metabolic	  pathways	  and	  protein	  interaction	  networks	  to	  reconstruct	  
gastric	   cancer	   specific	   pathways	   will	   help	   to	   identify	   molecular	   targets	   for	   repositioned	  
drugs.	   Differentially	   expressed	   genes	   identified	   from	   genomics	   data	   will	   be	   enriched	   for	  
KEGG	  pathways	   and	   known	  drug	   targets.	   Connectivity	  Map	   can	  be	   used	   to	   identify	   drugs	  
that	   target	   the	   enriched	   pathways.	   A	   topological	   network	   that	   connects	   drugs	   and	   their	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